WO2012116945A2 - Liquid phase separation of plasmid dna isoforms and topoisomers - Google Patents

Liquid phase separation of plasmid dna isoforms and topoisomers Download PDF

Info

Publication number
WO2012116945A2
WO2012116945A2 PCT/EP2012/053241 EP2012053241W WO2012116945A2 WO 2012116945 A2 WO2012116945 A2 WO 2012116945A2 EP 2012053241 W EP2012053241 W EP 2012053241W WO 2012116945 A2 WO2012116945 A2 WO 2012116945A2
Authority
WO
WIPO (PCT)
Prior art keywords
group
branched
unbranched
use according
ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2012/053241
Other languages
French (fr)
Other versions
WO2012116945A3 (en
Inventor
Michael LÄMMERHOFER
Wolfgang Lindner
Marek Mahut
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim RCV GmbH and Co KG
Original Assignee
Boehringer Ingelheim RCV GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim RCV GmbH and Co KG filed Critical Boehringer Ingelheim RCV GmbH and Co KG
Priority to JP2013555837A priority Critical patent/JP2014512805A/en
Priority to KR1020137023749A priority patent/KR20140033006A/en
Priority to SG2013065024A priority patent/SG192983A1/en
Priority to AU2012222502A priority patent/AU2012222502A1/en
Priority to EP12705871.7A priority patent/EP2680932A2/en
Priority to CA2825248A priority patent/CA2825248A1/en
Priority to CN201280020769.9A priority patent/CN103501871A/en
Publication of WO2012116945A2 publication Critical patent/WO2012116945A2/en
Publication of WO2012116945A3 publication Critical patent/WO2012116945A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D15/00Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08Selective adsorption, e.g. chromatography
    • B01D15/26Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D15/00Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08Selective adsorption, e.g. chromatography
    • B01D15/26Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361Ion-exchange
    • B01D15/363Anion-exchange
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/281Sorbents specially adapted for preparative, analytical or investigative chromatography
    • B01J20/286Phases chemically bonded to a substrate, e.g. to silica or to polymers
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30Processes for preparing, regenerating, or reactivating
    • B01J20/32Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
    • B01J20/3231Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
    • B01J20/3242Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
    • B01J20/3244Non-macromolecular compounds
    • B01J20/3246Non-macromolecular compounds having a well defined chemical structure
    • B01J20/3257Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one of the heteroatoms nitrogen, oxygen or sulfur together with at least one silicon atom, these atoms not being part of the carrier as such
    • B01J20/3263Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one of the heteroatoms nitrogen, oxygen or sulfur together with at least one silicon atom, these atoms not being part of the carrier as such comprising a cyclic structure containing at least one of the heteroatoms nitrogen, oxygen or sulfur, e.g. an heterocyclic or heteroaromatic structure
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J41/00Anion exchange; Use of material as anion exchangers; Treatment of material for improving the anion exchange properties
    • B01J41/20Anion exchangers for chromatographic processes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C12N15/1006Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
    • C12N15/101Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by chromatography, e.g. electrophoresis, ion-exchange, reverse phase
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2220/00Aspects relating to sorbent materials
    • B01J2220/80Aspects related to sorbents specially adapted for preparative, analytical or investigative chromatography
    • B01J2220/82Shaped bodies, e.g. monoliths, plugs, tubes, continuous beds

Definitions

  • the present invention relates to the chromatographic materials and methods for separation of isoforms, topoisomers, oligomeric and multimeric forms of plasmid DNA (pDNA) governed by use of carbamoyl-decorated anion-exchange ligands immobilized or embedded into a heterogeneous matrix.
  • pDNA plasmid DNA
  • Plasmid DNA is an extrachromosomal genetic unit providing its host cell with additional functionalities. Since the discovery of its great potential for use in gene therapy or genetic vaccination, much attention is paid to biotechnological production of these novel type of drugs (Schleef, M., Plasmids for Therapy and Vaccination, Wiley-VCH, Weinheim 2001). From more possible isoforms, the so- called covalently closed circular (ccc) form is considered to be most active for therapeutics.
  • ccc plasmid DNA is often produced by fermentation in E.coli followed by harvesting, alkaline lysis and multi-step purification of pDNA (Urthaler, J., et al., Journal of Biotechnology, 2007, 128, pgs: 132-149). For human gene therapy, all these steps must meet regulatory guidelines. Therefore the use of animal derived compounds (e.g. enzymes like hen egg white lysozyme) and/or toxic reagents shall be avoided. Furthermore, production processes have to guarantee a low level of host-related impurities (such as endotoxines in the case of bacterial host), see in Urthaler, J., Chemical Engineering & Technology, 2005, 28, pgs: 1408-1420.
  • host-related impurities such as endotoxines in the case of bacterial host
  • catenanes i.e. circular DNA that is interlaced together as links in a chain.
  • the catenated DNA is attached loop to loop in contrast to the concatenated DNA which is attached end to end.
  • ccc plasmids consist of a series of individual topological isomers (topoisomers), which differ by various degrees of supercoiling. These ccc topoisomers have different linking numbers, thus a different number of
  • Supercoiling consists of two quantities, twist (Tw) and writhe (Wr), which are interconvertible but for a certain topoisomer the sum of both is invariant.
  • Tw twist
  • Wr writhe
  • Bacterial plasmids a key element in biotechnology, molecular biology and the development of novel biopharmaceuticals and therapeutics, are negatively supercoiled in vivo.
  • the amount of supercoiling is around 6%, meaning that on average 6 negative supercoils are introduced per 100 helical turns of the most common type of DNA, so called B-DNA, under standard conditions, corresponding to 6 negative supercoils per 1050 base pairs on average (if the standardized value of 10.5 base pairs per turn is used for the calculation).
  • the topoisomer pattern was found to be changed during bacterial cells proliferation, in vivo according to a circadian rhythm (Woelfle, M.A., PNAS, 2007, 104, 47, pgs: 18819-18824).
  • GenPak FAX from Waters (Waters Corporation, Milford, Massachusetts, USA), employing the same basis material, i.e. non-porous 2.5 ⁇ particles composed of a hydrophilic organic polymer with diethylaminoethyl (DEAE)-based ligands. Topoisomer distribution can be analyzed so far by electrophoretic techniques only. Apart from that, there are neither materials nor methods (including chromatography) available in the state of the art for the separation of this type of ccc plasmid DNA.
  • any chromatographic method mainly depends on three essentials: (1) a length of separation compartment, e.g. column filled with chromatographic material, (2) retention factor (capacity factor) describing the migration rate of an analyte on a column, and (3) selectivity representing ratio between the retention factors of two species which are to be separated.
  • a length of separation compartment e.g. column filled with chromatographic material
  • retention factor capacity factor
  • selectivity representing ratio between the retention factors of two species which are to be separated.
  • selectivity is influenced by characteristics of supportive material (also known as solid phase/ matrix/ support) and of the nature of the ligand attached to or embedded into the support.
  • Porous supports with mid-sized pores (mesopores) used for small molecules do not allow the biomolecules to enter inside (Rozing, G. P., Journal of
  • cinchonan alkaloid ligands including cinchonan carbamates and cinchonan ureas were disclosed as chiral catalysts in asymmetric organic synthesis (WO92/20677 and US6197994B1), and as chiral discriminants (i.e. chiral selectors) in analytical chemistry (Laemmerhofer M., et al., Journal of Chromatography, A 1996, 741 , pgs: 33-48; W097/46557; US6616825 B1 ;
  • the invention relates to use of a material comprising a ligand according to formula 1
  • the ligand contains a cationic group (C) and a hydrogen donor group (N-H) connected by a spacer with a length between 3 to 5 atoms,
  • n, o and r are independently from one another either 0 or 1 , and
  • k, I, n and p are independently from one another either 0, 1 or 2, and
  • Y is any moiety selected from the group -CH 2 -, -0-, -NH- or -S-,
  • Z is any moiety selected from the group -C-, -S-, or -P- , and
  • RL R 2 and R 3 are anyone of the substituents from the group consisting of hydrogen, CMS branched or unbranched alkyl , C 2 -is branched or unbranched alkenyl, C 2 -is branched or unbranched alkynyl, C 3 .n-carbocycle , C 3 . 8 -heterocycle , C 5 .i 8 -aryl and C 5 .i 3 -heteroaryl,
  • R ⁇ R 2 and R 3 optionally comprise independently from one another one or more moieties selected from the group -S-, -0-, -NH-, and
  • each of R ⁇ R 2 , R 3 can be optionally and independently substituted with one or more substituents selected from the group consisting of hydrogen, Ci_ 6 branched or unbranched alkyl , C 2 . 6 branched or unbranched alkenyl, C 2 . 6 branched or unbranched alkynyl, C 3 . 8 -carbocycle , C 3 . 8 -heterocycle and C 5 .i 0 -aryl, C 5 .i 0 - heteroaryl, and
  • the cationic group C is a C 3 _n heterocycle comprising at least one nitrogen atom and optionally another heteroatom selected from the group consisting of sulphur, oxygen, nitrogen and phosphorus, or C 5 -i 8 heteroaryl comprising at least one nitrogen atom and optionally another heteroatom selected from the group consisting of sulphur, oxygen, nitrogen and phosphorus, or
  • CM 0 alkyl branched or unbranched C 2 -io alkenyl, branched or unbranched C 2 -io alkynyl comprising at least one nitrogen atom and optionally another heteroatom selected from the group consisting of sulphur, oxygen, nitrogen and phosphorus, wherein C and R 3 or C and R 2 are optionally linked to each other by forming a ring, and
  • ligand is optionally immobilized onto or embedded into a matrix via or R 3 group
  • the invention relates to the methods for separation of plasmid DNA isoforms including covalently closed circular (ccc), open circular (oc) and linear (lin) forms, oligomeric and multimeric forms such as monomers, dimers, trimers, tetramers, oligomers, multimers, and/or ccc topoisomers by using of the materials according to the invention.
  • covalently closed circular (ccc), open circular (oc) and linear (lin) forms oligomeric and multimeric forms such as monomers, dimers, trimers, tetramers, oligomers, multimers, and/or ccc topoisomers by using of the materials according to the invention.
  • a material according to the invention comprising a carbamoyl-decorated anion exchange ligand immobilized or embedded into a heterogeneous matrix can be used for the separation of isoforms, topoisomers, oligomeric and multimeric forms of plasmid DNA (pDNA).
  • pDNA plasmid DNA
  • the invention provides a material which comprises a ligand according to formula 1
  • the ligand contains a cationic group (C) and a hydrogen donor group (N-H) connected by a spacer with a length between 3 to 5 atoms,
  • n, o and r are independently from one another either 0 or 1 , and
  • k, I, n and p are independently from one another either 0, 1 or 2, and
  • Y is any moiety selected from the group -CH 2 -, -0-, -NH- or -S-,
  • Z is any moiety selected from the group -C-, -S-, or -P- , and
  • RL R 2 and R 3 are anyone of the substituents from the group consisting of hydrogen, CMS branched or unbranched alkyl , C 2 -is branched or unbranched alkenyl, C 2 -is branched or unbranched alkynyl, C 3 .n-carbocycle , C 3 . 8 -heterocycle , C 5 .i 8 -aryl and C 5 .i 3 -heteroaryl,
  • R ⁇ R 2 and R 3 optionally comprise independently from one another one or more moieties selected from the group -S-, -0-, -NH-, and
  • each of R ⁇ R 2 , R 3 can be optionally and independently substituted with one or more substituents selected from the group consisting of hydrogen, Ci_ 6 branched or unbranched alkyl , C 2 . 6 branched or unbranched alkenyl, C 2 . 6 branched or unbranched alkynyl, C 3 . 8 -carbocycle , C 3 . 8 -heterocycle and C 5 .i 0 -aryl, C 5 .i 0 - heteroaryl, and
  • the cationic group C is a C 3 _n heterocycle comprising at least one nitrogen atom and optionally another heteroatom selected from the group consisting of sulphur, oxygen, nitrogen and phosphorus, or
  • C 5 .i 8 heteroaryl comprising at least one nitrogen atom and optionally another heteroatom selected from the group consisting of sulphur, oxygen, nitrogen and phosphorus, or
  • CM 0 alkyl branched or unbranched C 2 _i 0 alkenyl, branched or unbranched C 2 _i 0 alkynyl comprising at least one nitrogen atom and optionally another heteroatom selected from the group consisting of sulphur, oxygen, nitrogen and phosphorus, wherein C and R 3 or C and R 2 are optionally linked to each other by forming a ring, and
  • ligand is optionally immobilized onto or embedded into a matrix via or R 3 group
  • N A represents the nitrogen atom of the cationic group
  • Y is an oxygen (-0-) thus yielding a carbamate group or
  • RL R 2 , R3 are anyone of the substituents selected from the group consisting of hydrogen, CMS branched or unbranched alkyl , C 2 -is branched or unbranched alkenyl, C 2 -is branched or unbranched alkynyl, C 3 .n-carbocycle , C 3 . 8 -heterocycle , C 5 .i 8-aryl and C 5 .i 3 -heteroaryl,
  • R ⁇ R 2 and R 3 optionally comprise independently from one another one or more moieties selected from the group -S-, -0-, -NH-, and
  • R ⁇ R 2 and R 3 can be optionally and independently substituted with one or more substituents selected from the group consisting of hydrogen, Ci_ 6 branched or unbranched alkyl , C 2 . 6 branched or unbranched alkenyl, C 2 . 6 branched or unbranched alkynyl, C 3 . 8 -carbocycle , C 3 . 8 -heterocycle and C 5 .i 0 -aryl, C5.10- heteroaryl, and
  • substitution optionally comprises the anchoring to a matrix via or for the separation of plasmid DNA or topoisomers.
  • Y -0-
  • Ri is alkyl immobilized to silica or thiolpropyl-modified silica
  • R 2 is methoxyquinoline
  • R 3 is ethyl or vinyl.
  • material refers to and comprises a carbamoyl-decorated anion exchange type of ligands optionally immobilized onto or embedded into a heterogeneous (solid or liquid) matrix such as a
  • Carbamoyl in the meaning of the present invention does not preclude other isosteric functional groups consisting of a hydrogen-donor acceptor system such as sulphonamide, phosphonamide and similar functionalities, as defined by the formula 2.
  • ligand refers to and comprises a chemical structure, which is bound via a linker or embedded into a matrix and is able to interact with plasmid DNA.
  • the preferred embodiment of the ligand is quincorine- or quincoridine carbamate, or quincorine- or quincoridine urea.
  • one of the more preferred embodiments is cinchonan carbamate or cinchonan urea, most preferred is quinine- or quinidine carbamate, in particular propyl carbamoyl quinine or quinidine, te/f-butylcarbamoyl-quinine or quinidine, and allylcarbamoyl-10, 11-dihydroquinine or quinidine.
  • quinine- or quinidine carbamate in particular propyl carbamoyl quinine or quinidine, te/f-butylcarbamoyl-quinine or quinidine, and allylcarbamoyl-10, 11-dihydroquinine or quinidine.
  • optionally substituted is intended to mean that a hydrogen atom of a methylene group or a hydrogen atom of an aromatic or heteroaromatic ring is substituted with a different organic or inorganic substituent.
  • Ci-i 8 -alkyl herein means a saturated branched or unbranched hydrocarbon chain of 1-18 carbon atoms.
  • Ci -6 -alkyl herein means a saturated branched or unbranched hydrocarbon chain of 1-6 carbon atoms.
  • C 2 .i 8 -alkeny herein means an unsaturated branched or unbranched hydrocarbon chain of 2-18 carbon atoms, which comprises at least one double bond.
  • C 2 -6-alkenyl herein means an unsaturated branched or unbranched hydrocarbon chain of 2-6 carbon atoms, which comprises at least one double bond.
  • C 2 .i 8 -alkyny is intended to mean an unsaturated branched or unbranched hydrocarbon chain of 2-18 carbon atoms, which comprises at least one triple bond.
  • C 2 -6-alkynyl herein is an unsaturated branched or unbranched hydrocarbon chain of 2-6 carbon atoms, which comprises at least one triple bond.
  • branched is intended to mean that at least one atom of the hydrocarbon chain, optionally comprising a chain atom is selected from sulphur, oxygen or nitrogen, is covalently bound to another chain atom.
  • unbranched is intended to mean that any atom of the hydrocarbon chain, optionally comprising a chain atomis selected from sulphur, oxygen or nitrogen, is not covalently bound to any other chain atom.
  • chain atom within the meaning of the present invention relates to an atom that exhibits two separate bonds, such as carbon, sulphur, oxygen or nitrogen.
  • C 3 -n-carbocycle is intended to mean an aliphatic hydrocarbon 3-11 carbon ring atoms.
  • C 3 . 8 -carbocycle is intended to mean an aliphatic hydrocarbon 3-8 carbon ring atoms.
  • C 3 . 8 -heterocycle is a carbocycle comprising 3-8 ring atoms, where at least one of the ring atoms is not carbon but an atom selected from N, O, or S.
  • C 5 -i 8 -ary is an aromatic hydrocarbon ring with 5-18 ring atoms.
  • C 5 .io-aryl is an aromatic hydrocarbon ring with 5-10 ring atoms.
  • C 5 .i 3-heteroaryl is an aromatic ring with 5-13 ring atoms, wherein at least one ring atom is not carbon but an atom selected from N, O or S.
  • C 5 .io-heteroaryl is an aromatic ring with 5-10 ring atoms, wherein at least one ring atom is not carbon but an atom selected from N, O or S.
  • Ci_ 8 branched or unbranched alkyl C 2 . 8 branched or unbranched alkenyl and C 2 . 8 branched or unbranched alkynyl, optionally comprising one or more sulphur atoms.
  • R 3 is anyone of the substituents selected from the group consisting of hydrogen, Ci_ 8 branched or unbranched alkyl , C 2 . 8 branched or unbranched alkenyl and C 2 . 8 branched or unbranched alkynyl, optionally comprising one or more sulphur atroms.
  • R 2 is anyone of the substituents selected from the group consisting of hydrogen, C 5 .i 0 -aryl and C 5 . 9 -heteroaryl.
  • anchoring to a matrix is intended to mean any substituent that forms a stable connection between the ligand and the matrix or between the ligand and residues that are attached to the matrix.
  • molecular weight refers to the sum of the relative atomic masses of the constituent atoms of the ligand according to the invention.
  • molecular weight of the ligand is between 200 to 2000Da, more preferably between 250 to 1200Da, most preferably between 400 to 700 Da.
  • the "cationic group C" is a C 3 .n heterocycle comprising at least one nitrogen atom and optionally another heteroatom selected from the group consisting of sulphur, oxygen, nitrogen and phosphorus, or
  • C 5 .i 8 heteroaryl comprising at least one nitrogen atom and optionally another heteroatom selected from the group consisting of sulphur, oxygen, nitrogen and phosphorus, or
  • branched or unbranched C M0 alkyl branched or unbranched C 2 -io alkenyl, branched or unbranched C 2 -io alkynyl comprising at least one nitrogen atom and optionally another heteroatom selected from the group consisting of sulphur, oxygen, nitrogen and phosphorus,
  • C and R 3 or C and R 2 are optionalloy linked to each other by forming a ring.
  • ring within the meaning of the invention refers to mono-, bi-, polycyclic or spirocyclic rings.
  • the cationic group is incorporated into a cyclic or bicyclic ring system.
  • the bicyclic ring system is tropane, (hydro)quinolizidine, (hydro)pyrrolizidine, 1-aza-adamantane, azabicyclo[3.2.1]octane, azabicyclo[3.2.1]nonane, azabicyclo[3.3.1]nonane, (hydro)indolizidine,
  • cationic group within the meaning of the present invention further refers to a moiety containing one nitrogen atom bearing a partial or permanent positive charge selected from a group consisting of tertiary-, quaternary-, secondary-, primary amine or guanidine, amidine and (hetero)aromatic amino group.
  • a preferred embodiment of the cationic group represents aliphatic amine, more preferred quaternary amine, most preferred tertiary amine.
  • the teriary amine is a part of quinuclidine.
  • hydrogen donor moiety refers to a combination of a hydrogen atom bound to an electronegative atom such as nitrogen, oxygen or fluorine.
  • hydrogen acceptor group refers to an electronegative atom such as oxygen, nitrogen, fluorine or sulphur with at least one free electron pair.
  • spacer within the meaning of the present invention refers to a group of adjacent atoms of a specified number being bound on either side to functionally important entities, namely a cationic group (C) on one side and a hydrogen donor moiety (N-H) on the other side.
  • C cationic group
  • N-H hydrogen donor moiety
  • the number of adjacent atoms is counted as a shortest distance through an atom chain.
  • the length of the spacer is between 3 and 5 atoms. In the most preferred embodiment the length of the spacer is equal to 4 atoms.
  • the ligand according to the invention is located not further than 6 atoms from the matrix.
  • immobilized within the meaning of the present invention refers to a covalent bonding onto a solid or liquid matrix (support).
  • embedded within the meaning of the present invention refers to a non- covalent inclusion into the solid or liquid matrix (support).
  • anchoring to a matrix is intended to mean any substituent that forms a stable connection between the ligand and the matrix or between the ligand and residues that are attached to the matrix.
  • heterogeneous matrix within the meaning of the present invention relates to a matrix (support) that cannot be unified with the solvent containing dissolved plasmid DNA being either insoluble or immiscible.
  • Plasmid DNA refers to an extrachromosomal genetic unit consisting of double stranded deoxyribonucleic acid.
  • isoforms within the meaning of the present invention refers to the different forms of plasmid DNA of equal molecular weight selected from the group of covalently closed circular (ccc), open circular (oc) and linear (lin) plasmid.
  • ccc covalently closed circular
  • oc open circular
  • Lin linear
  • oligomeric and multimeric within the meaning of the present invention relate to different forms of plasmid DNA of different molecular weight originating from the combination of monomeric isoforms into a larger molecule, the molecular weight of which is an integral multiple of that of the monomer. Subsequently, the term oligomeric marks combinations of two, three or four monomers, while the term multimeric marks combinations of five and more monomers.
  • the oligomeric and multimeric combinations may be either in form of catenane or concatemer.
  • catenane refers to circular DNA that is interlaced together as links in a chain.
  • conjugate refers to long continuous DNA molecule that contains multiple copies of the same DNA sequences linked in series.
  • topoisomers within the meaning of the present invention refers to a covalently closed circular (ccc) plasmid DNA molecules with a different degree of supercoiling, described by the topological linking number or linking number difference. Topoisomers of one individual plasmid have equal molecular weight and connectivity. The associated analysis of such topoisomers should be denoted as topology analysis or topoisomer analysis.
  • separation within the meaning of the present invention relates to a segregation of different forms of plasmid DNA such as isoforms, topoisomers, oligomeric and multimeric forms based on different affinities of these forms to the ligand (referred to as chemoaffinity principle).
  • chromatography refers to a set of separation techniques employing two heterogeneous phases, while one phase, the so called mobile phase, is moving along the other phase, the so called stationary phase.
  • Preferred embodiment is the material according to the invention wherein the hydrogen donor N-H is located adjacent to a hydrogen acceptor group.
  • adjacent in the meaning of the present invention denotes a direct connection between two atoms or atom groups by a single covalent bond.
  • the hydrogen acceptor and hydrogen donor group form part of amide, carbamate, urea, phosphonamide or sulphonamide group.
  • the plasmid DNA comprises mixtures of any components selected from the group consisting of ccc and its topoisomers, oc, lin, dimer, trimer, tetramer, oligomer, multimer (in form of catenane or concatemer) independent from the size of the plasmid and its nucleotide sequence.
  • matrix encompasses a solid support capable of attaching a ligand, or a liquid capable of dissolving the ligand.
  • solid matrix within the meaning of the present invention refers to a solid support suitable for the desired chromatographic separation or liquid-solid extraction, selected from a group of inorganic polymers or organic polymers, preferably micropelicullar silica-based particles.
  • micropelicullar refers to a non-porous matrix particle which is characterized by a core of fluid-impervious support material (fused-silica particles or organic polymer microspheres) covered by a thin, retentive layer of stationary phase.
  • the thin retentive layer of stationary phase can be obtained by roughening the surface and attaching the respective chromatographic ligand to obtain an adsorption surface that can retain the target solutes.
  • liquid matrix refers to a liquid selected from a group of apolar solvents such as alkanes, cycloalkanes, or polymeric liquids such as polysiloxanes, polyethyleneoxides, or a polymeric liquid such as polysiloxane or polyethylenoxide diluted in another solvent.
  • apolar solvents such as alkanes, cycloalkanes, or polymeric liquids such as polysiloxanes, polyethyleneoxides, or a polymeric liquid such as polysiloxane or polyethylenoxide diluted in another solvent.
  • the matrix according to the invention is selected from organic or inorganic polymers.
  • organic polymers refers to a solid organic polymer such as
  • poly(meth)acrylate and its copolymers polystyrene and its copolymers, poly(meth)acrylamide and its copolymers, ring-opening methathesis polymers, polysaccharides and its copolymers such as agarose, and bears chemical groups at the polymer surface capable of a covalent attachment of a spacer and/or a ligand.
  • inorganic polymers refers to a solid inorganic polymer such as silicon oxide (silica), titanium oxide, germanium oxide, zirconium oxide, aluminium oxide and glass.
  • the polymer surface is capable of a covalent attachment of a spacer and/or a ligand.
  • the solid matrix is a particle, a monolith resin, a membrane, or a magnetic bead.
  • particle refers to a solid matrix structure of various sizes and morphological features including but not limited to irregular, regular, spherical, porous, non-porous, micropellicular. Usually there is a large number (> 1000) of individual particles within one separation compartment.
  • monolith resin refers to a solid matrix structure containing flow-through channels allowing for convective flow, also called macropores, optionally containing smaller-sized pores additionally such as mesopores and micropores. Usually there is a single piece or only a small number ( ⁇ 10) of individual monolith resins in one separation compartment.
  • membrane refers to a solid matrix in the shape of a thin layer being permeable for the solvent and semi-permeable for the solutes include the sample components.
  • the membrane is selected from the group of polysaccharides such as cellulose, cellulose ester, poly(meth)acrylates, poly(styrenes),
  • polytetrafluoroethylene polysulfone, polyacrylonitril, polyphenylenoxide, polyethylene, polyropylen, teflon, polyethyleneterephthalate, polyvinylidenchlonde, PVC, polyimide, PVA, polycarbonate.
  • magnetic bead refers to a particle composed of a magnetic or ferromagnetic inner core and an outer solid matrix shell, which is attracted when a magnetic field is applied.
  • the preferred embodiment of the material according to the invention is selected from a group consisting of:
  • the substructure on the left hand side represents the supporting matrix and the substructure on the right hand side of the dotted line represents the ligand.
  • the substructure on the left hand side represents the supporting matrix and the substructure on the right hand side of the dotted line represents the ligand.
  • the substructure on the left hand side represents the supporting matrix and the substructure on the right hand side of the dotted line represents the ligand.
  • the substructure on the right hand side represents the supporting matrix and the substructure on the left hand side of the dotted line represents the ligand.
  • the substructure on the right hand side represents the supporting matrix and the substructure on the left hand side of the dotted line represents the ligand.
  • the substructure on the right hand side represents the supporting matrix and the substructure on the left hand side of the dotted line represents the ligand.
  • the separation of all three pDNA isoforms or topoisomers is governed by the material comprising carbamoyl-decorated anion-exchange ligands, which have not been employed so far for this type of liquid phase separation.
  • These ligands according to the invention comprise a well defined arrangement of a NH-donor, H-acceptor, and the anion exchange site. Hence the plasmid isoforms/
  • topoisomers interaction with the material comprising the ligand(s) is directed in a defined way, ensuring an invariant elution order.
  • the present invention claims a new reliable and predictable concept for separation of very large biomolecules based on chemoaffinity principles.
  • the ccc topoisomers have a potential to represent an additional quality control parameter in the biotechnological production including the final product characterization.
  • Chromatographic ligands suitable for plasmid DNA separation are designed in order to make an easy attachment to the matrix possible (Example 1), wherein a ligand containing a terminal alkene group reacts with a thiol group in a radical addition reaction.
  • a linker is attached to the matrix containing a terminal thiol group.
  • the matrix and the alkene-containing ligand are mixed in the presence of a radical initiator to give a stable thio-ether bond between the ligand and the linker bound to a matrix (see structure a). Using this process, stable chromatographic materials are easily obtained with a high ligand coverage on the matrix surface.
  • the first one is anchored via a short propyl-linker between the ligand and the silica matrix (4 bonds between the first silicon atom of the matrix and the NH hydrogen donor, see structure b), and the other one via a long linker (8 bonds between the first silicon atom of the matrix and the NH hydrogen donor, see structure c) to the thiopropyl-modified silica matrix.
  • a short propyl-linker between the ligand and the silica matrix bonds between the first silicon atom of the matrix and the NH hydrogen donor, see structure b
  • a long linker 8 bonds between the first silicon atom of the matrix and the NH hydrogen donor, see structure c
  • the main difference is the length of the linker (3 atoms versus 7 atoms), i.e. the distance between the ligand and the surface of the matrix is not identical.
  • the material containing the short linker complete recoveries of all isoforms including the oc form are found due to proximity of negatively charged remaining silanols which have a repulsing effect on pDNA.
  • these data show overall improvement (superiority) of the material properties in terms of resolution between oc and ccc form as well as in terms of oc recovery of the material when compared to the commercially available columns currently used for pDNA isoform analysis.
  • the long-linked ligand described in the previous paragraph is attached via the long linker to the following silica-based matrixes: 1.5 ⁇ non-porous particles, 10 ⁇ porous particles and a monolith (Example 3).
  • Columns containing these materials are tested in the analogical experimental setup as disclosed in the previous paragraph.
  • the samples containing all three isoforms of pDNA oc, ccc and lin isoforms of the pMCP1 plasmid
  • All tested matrixes are suitable for separating the ccc isoform from the oc isoform and for separating the ccc isoform from the lin isoform.
  • 1.5 ⁇ matrix an efficient separation between the oc and linear isoforms is achieved (see in Figure 1 a).
  • the 1.5 ⁇ support is the preferred choice.
  • the 10 ⁇ porous matrix (see Figure 1 b) and the monolithic support (see Figure 1 c) both are suitable for preparative applications focusing merely on the separation of ccc form. In spite of the coelution of the oc and lin isoforms, still effective separation of the ccc form is achieved in this case.
  • chromatographic selectivity calculated as retention time difference between the highest abundant topoisomers is found to be equal (0.12 ⁇ 0.02) on all tested supports. This shows the importance of the chemoaffinity separation principle resulting in high robustness of the separation.
  • the 1.5 ⁇ matrix provides the highest separation efficiency due to small peak width and is thus the preferred choice for analytical purposes.
  • Example 4 compares two different methods for pDNA separation, namely Method 1 by using of the increasing gradient of sodium chloride (NaCI) and Method 2 with the increasing pH gradient. In both cases a chromatographic column containing the material based on 1.5 ⁇ non-porous particles
  • Method 2 is preferred for the analytical determination of the plasmid homogeneity, i.e. the content of the ccc form relatively to the other forms (oc and lin), independent on the size of the plasmid, as well as for preparative application for isolation of ccc pDNA (without topoisomer separation), due to its narrow peak form compared to NaCI-mediated elution and lower salt loads of the collected fractions.
  • topoisomers The elution pattern of topoisomers is assessed by analyzing the eluted fractions using a complementary method, capillary gel electrophoresis (Example 6). During the elution of individual topoisomers, it is found that those which are being less negatively supercoiled elute firstly. Accordingly, topoisomers with a higher negative supercoiling elute later, shown by separating the isolated
  • the topoisomer patterns for the pMCP1 plasmid (4.9 kbp) following the Boltzmann distribution, are also recorded employing the column containing a propylcarbamoylquinine ligand by analyzing commercially available plasmids such as pUC19 (2.7 kbp, Sigma Aldrich), pBR322 (4.4 kb, Sigma Aldrich), pET-40b(+) (6.2 kbp, Invitrogen), or pBACsurf-1 (9.5 kbp, Invitrogen).
  • a plasmid topoisomer pattern is studied over the time course of the plasmid fermentation (Example 7).
  • Cell mass samples containing bacterial cells are disrupted using NaOH/SDS.
  • the suspension is centrifuged to obtain the cytoplasm content containing pDNA.
  • Two-dimensional high-performance liquid chromatography (HPLC) approach is used, wherein in the first step a total pDNA is isolated from the mixture using size exclusion chromatography (SEC) and in the second dimension an allylcarbamoyl-10,1 1-dihydroquinine ligand-containing silica (shown in structure c) column is employed for ccc topoisomer separation.
  • SEC size exclusion chromatography
  • Figures 1 a to 1 c Chromatograms recorded by UV absorption at 258 nm analyzing pDNA samples containing a mixture of ccc with oc and lin isoforms of the pMCP1 plasmid (4.9 kbp) during identical elution conditions.
  • Figure 2 Chromatogram recorded by UV absorption at 258 nm from pDNA samples containing ccc, oc and lin isoforms of the pMCP1 plasmid (4.9 kbp) during pH- and 2-propanol mediated gradient elution conditions.
  • the ccc form in these chromatograms eluting after the oc isoform, is split into a set of individual topoisomers.
  • the resolution between the topoisomers is higher when using the te/f-butylcarbamoyl-quincorine ligand immobilized to
  • Figure 3c Chromatogram recorded by UV absorption at 258 nm after loading 284 Mg of a pDNA samples with a high ccc content of the pMCP1 plasmid (4.9 kbp). Elution is accomplished via NaCI gradient employing a
  • the first peak represents the open circular (oc) isoform, while 21 topoisomers of the ccc isoform elute afterwards.
  • "Y" axis reflects concentration of pDNA isoforms detected as UV absorption at 258 nm in absorption units [AU] in relation to "X" axis corresponding to retention time [min].
  • Figure 4a Overlay of chromatograms recorded by UV absorption at 258 nm analyzing pDNA samples with a high ccc content of the pMCP1 plasmid (4.9 kbp) during NaCI-mediated elution employing a triethoxysilyl-activated propylcarbamoylquinine-ligand bound to 1.5 ⁇ non-porous silica.
  • the ccc form in these chromatograms eluting after the oc isoform, is split into a set of individual topoisomers.
  • a and B represent isolated topoisomer fractions.
  • the dashed lines stand for fractions A and B reinjected after previous fractionation of the eluted topoisomers on the same column.
  • "Y" axis reflects concentration of pDNA isoforms detected as UV absorption at 258 nm in milliabsorption units
  • Figure 4b Capillary electrophorectic separation of the mixturecontaining fractions A and B, wherein the fractions are identical to A and B shown in Figure 4a.
  • Y axis reflects concentration of pDNA isoforms detected as UV absorption at 258 nm in milliabsorption units [mAU] in relation to "X" axis corresponding to retention time [min].
  • Figure 5b The maximum of the topoisomer distribution (calculated as maximum peak area) denoted as a relative linking number of the highest abundant topoisomer which is a measure of the overall supercoling (at the beginning of fermentation this value is zero) (y axis) is plotted against the entire duration of the fermentation (x axis).
  • ⁇ " axis stands for the relative linking number ALk in relation to "X" axis reflecting the duration time [hours].
  • Example 1 Scheme for synthesis of a ligand and coupling to a solid matrix.
  • Scheme 1 980 mg (5 mmol) of (R)-(-)-1-Benzyl-3-hydroxypiperidine (Sigma Aldrich) are transferred into a three-necked round bottom flask and dissolved in 15 ml dichloromethane. The apparatus is flushed with nitrogen, and 502 ⁇ (5.7 mmol, 1.15 eq.) allylisocyanate (Fluka) together with 3 ⁇ (5 ⁇ )
  • 3-mercaptopropyl-modified silica matrix (or support) is produced from bare 5 ⁇ spherical silica (30 g, Daiso, Japan) and 3-mercaptopropyl-methyldimethoxysilane (8.6 ml) by refluxing in dry toluene in the presence of 4-dimethylaminopyridine (57 mg, Fluka) for 7 hours. Endcapping is performed by refluxing the generated 3-mercaptopropyl-modified silica with 1 ,1 , 1 ,3,3,3-hexamethyldisilazane (Fluka) in toluene for 3 hours to form trimethylsilyl (TMS)-endcapped silanols.
  • TMS trimethylsilyl
  • reaction buffer is prepared by dissolving 178 mg disodiumhydrogenphosphate (Merck) in a mixture of 20 ml distilled water and 5 ml 2-propanol (Roth). The pH is adjusted to 8.0 with diluted orthophosphoric acid. 132.6 mg Suprema-Gel 30u (Polymer Standards Service-USA, Inc.) are suspended in 1.8 ml reaction buffer. Then, 192 ⁇ of a solution of NaSH hydrate (Sigma Aldrich) in reaction buffer (100 mg/ml) is added, and the mixture is stirred for 2 hours at 63°C in a thermomixer
  • the modified material is washed twice with reaction buffer, twice with water, once with 0.1 mol/l HCI, again with water, and twice with methanol.
  • TCEP buffer is prepared by dissolving 672 mg sodiumdihydrogenphosphate in a mixture of 1 1.8 ml water and 2.8 ml methanol (measured pH is 4.6). Then, 19 mg (75 ⁇ ) tris(2-carboxyethyl)- phosphine hydrochloride (TCEP) (Fluka) are dissolved in 1 ml of TCEP buffer. 34.5 mg of thiol-modified Suprema Gel is added to the solution and the mixture is stirred overnight at room temperature. The suspension is filtered through a small funnel and the material is washed with TCEP buffer, methanol and finally with hexane. Elemental analysis (54.52% carbon, 7.67% hydrogen, 1.40% sulphur) revealed a sulphur concentration of 0.44 mmol/g while no nitrogen is present. The concentration of reactive thiols is 0.14 mmol/g, as determined
  • Ligand-modification 14.4 mg of reduced thiol-modified Suprema-Gel 30u are transferred into a safe-lock plastic reaction tube (eppendorf). 130 ⁇ of a 3.2 mg/ml solution of te/f-butylcarbamoylquinine (produced in-house) in methanol, 10 ⁇ of a 2 mg/ml solution of AIBN (Merck) in methanol and 0.36 ml methanol are added and the mixture is purged with nitrogen. The reaction tube is stirred at 65°C for 18h. The suspension is filtered through a small funnel and the material is washed 3x with methanol and finally with petroleumether.
  • a safe-lock plastic reaction tube eppendorf. 130 ⁇ of a 3.2 mg/ml solution of te/f-butylcarbamoylquinine (produced in-house) in methanol, 10 ⁇ of a 2 mg/ml solution of AIBN (Merck) in methanol
  • Elemental analysis (50.27% carbon, 7.70% hydrogen, 0.11 % nitrogen, 0.97% sulphur) reveals a successful immobilization of the te/f-butylcarbamoylquinine ligand onto the thiol-modified organic polymer matrix (structure g).
  • Example 2 Impact of the linker's length on the recovery of plasmid isoforms.
  • Two solid supports for chromatography are synthesized bearing quinine- carbamate ligands, onto one of which the ligand is anchored via a short linker to the matrix (triethoxysilyl-activated propylcarbamoylquinine on bare silica, structure b), and onto the other matrix via a long linker (9-allylcarbamoyl-10, 11- dihydroquinine on 3-mercaptopropyl-modified silica, see structure c).
  • the support with the long linker is synthesized according to Example 1 , Scheme 1 , starting from 10, 11-dihydroquinine (Buchler, Germany) and allylisocyanate (Sigma Aldrich) in 95% yield and attached to endcapped 3-mercaptopropyl-modified silica.
  • the ligand density according to the elemental analysis (14.01 % C, 2.18% H, 1.38% N, and 1.90% S) is 318 ⁇ /g.
  • 3-isocyanatopropyl-triethoxysilane (1 mol eq.) and quinine (1.05 mol eq.) are refluxed in methanol to yield the carbamate-containing product.
  • Bare 5 ⁇ spherical silica is added directly to the mixture (0.5 g of bare silica per mmol of quinine) while stirring mechanically and the suspension is refluxed further to obtain triethoxysilylpropylcarbamoylquinine-modified silica.
  • the silanol groups are endcapped according to example 1 , scheme 1.
  • the ligand density according to the elemental analysis (7.90%C, 1.21 % H, 0.911 % N) is 217 ⁇ ⁇ /g.
  • HPLC columns containing the produced supports are packed in-house with the modified 5 ⁇ silica stationary phases, at a pressure of 600 bar.
  • HPLC analyses are carried out on an Agilent 1200 SL system (Waldbronn, Germany) equipped with a binary pump, a thermostatted autosampler (cooled to 4°C) and a DAD UV detector using a D 2 lamp as UV source. Sample components are eluted by using Method 1 , i.e. an increasing NaCI gradient and an increasing 2-propanol gradient simultaneously ("mixed NaCI and 2-propanol gradient").
  • Eluents for HPLC and chromatographic conditions Firstly, a 0.5 mol/L stock solution from NaH 2 P0 4 (Merck) is prepared. Eluent A consisted of 1 : 10 diluted stock solution (50 mmol/L NaH 2 P0 4 ) titrated to 7.0 with 5M NaOH. Eluent B consisted of 1 : 10 diluted stock solution (50 mmol/L NaH 2 P0 4 ) containing 0.6 mol/L NaCI (Fluka) and 10% (v/v) isopropanol (Roth) titrated to 7.0 with 5M NaOH. A gradient from 0 to 100%B in 15 minutes is run during analysis.
  • the flow rate is set to 0.7 ml/min, detection wavelength to 258 nm (slit: 4nm, reference 360 nm with 100 nm bandwidth) and the temperature to 50°C (with preheating of the solvent in the 3 ⁇ heat exchanger).
  • a te/f-butylcarbamoylquinine ligand synthesized from te/f-butylisocyanate and quinine in accordance to the procedure as described in Example 2 is attached via 3-mercaptopropylsilane activated support to 1.5 ⁇ non-porous silica particles (obtained from Micra Scientific Inc., USA), to 10 ⁇ porous silica particles
  • Samples containing all three isoforms are prepared by mixing 60 ⁇ aqueous solution with 10 mM ethylenediaminetetraacetic acid disodium salt ("EDTA Na 2 ", Fluka), 10 ⁇ of a 2.84 g/ ⁇ ccc pDNA sample containing about 10% oc isoform, with 50 ⁇ 0.05 g/ ⁇ linear isoform.
  • Linear isoform is generated by digestion with EcoR V (Sigma Aldrich) according to the manufacturer's instructions and EDTA is added for inactivation of the endonuclease.
  • Example 4 Chromatographic method using a mixed pH and 2-propanol gradient elution (Method 2) in comparison to mixed NaCI / 2-propanol gradient elution (Method 1 ).
  • sample components are eluted using Method 2, i.e. an increasing pH gradient and an increasing 2-propanol gradient simultaneously ("mixed pH and 2-propanol gradient") on an Agilent 1200 SL system recording the UV absorption at 258 nm.
  • Eluents for HPLC and chromatographic conditions First, a 0.5 mol/L stock solution from NaH 2 P0 4 (Merck, Darmstadt, Germany) is prepared. Eluent A consisted of 1 :10 diluted stock solution (50 mmol/L NaH 2 P0 4 ) titrated to 7.2 with 5M NaOH. Eluent B consisted of 1 : 10 diluted stock solution (50 mmol/L NaH 2 P0 4 ) and 20% (v/v) 2-propanol titrated to 7.9 with 5M NaOH. A linear gradient from 0 to 100%B (corresponding to a gradient from pH 7.2 to pH 7.9) in 15 minutes is run during analysis.
  • the column is washed by a plug of sodium chloride (injection of 50 ⁇ 3M NaCI (aq.)) while the mobile phase composition is kept at 80% B for 1 minute, followed by reequilibration to 0% B for 5 minutes.
  • the flow rate is set to 0.7 ml/min, detection wavelength to 258 nm (slit 4 nm, reference 360 nm with 100 nm bandwidth) and the temperature to 60°C (with preheating of the solvent in the 3 ⁇ heat exchanger).
  • Method 2 is preferred for the analytical determination of the plasmid homogeneity, i.e. the content of the ccc form relatively to the other forms (oc and linear), as well as for preparative application for isolation of ccc pDNA (without topoisomer separation).
  • Example 5 Demonstration of ligand variation and high loadability.
  • the tert- butylcarbamoyl-quincorine ligand (structure d) is synthesized according to Example 1 , Scheme 1 , starting from quincorine (Buchler, Germany) and tert- butylisocyanate and performing flash silica column chromatography in ethyl acetate (redistilled in-house) / triethylamine (Fluka) (10:1) in 96% yield and attached to endcapped mercaptopropyl-modified 5 ⁇ silica particles.
  • the ligand density according to the elemental analysis (10.51 % C, 1.98% H, 0.979% N, 1.85% S) is 307 ⁇ /g.
  • the te/f-butylquincorinylurea ligand (structure e) is synthesized according to Example 1 , Scheme 1 , starting from quincorine-amine (Buchler, Germany) and te/f-butylisocyanate and performing flash silica column chromatography in ethyl acetate (redistilled in-house) / methanol / triethylamine (Fluka) (10: 1 :1) in 96% yield and attached to endcapped 3-mercaptopropyl-modified 5 ⁇ silica particles.
  • the ligand density according to the elemental analysis (8.965% C, 1.87% H, 0.979% N, 1.94% S) is 210 ⁇ /g.
  • the triethoxysilylpropylcarbamoylquinine-modified silica matrix is produced according to Example 2, using 1.5 ⁇ non-porous silica particles (Micra Scientific Inc., USA).
  • the ligand density according to the elemental analysis is 9 ⁇ /g due to 100 x smaller specific surface area.
  • the triethoxysilylpropylcarbamoylquinine- modified silica material is packed into 4.6 x 50 mm columns, while the other two materials are packed into 150 x 4.0 mm columns.
  • Eluents for HPLC and chromatographic conditions Firstly, a 0.5 mol/L stock solution from NaH 2 P0 4 (Merck) is prepared. Eluent A consisted of 1 : 10 diluted stock solution (50 mmol/L NaH 2 P0 4 ) titrated to 7.0 with 5M NaOH. Eluent B consisted of 1 : 10 diluted stock solution (50 mmol/L NaH 2 P0 4 ) containing 0.6 mol/L NaCI (Fluka) and 30% (v/v) isopropanol (Roth) titrated to 7.0 with 5M NaOH. A gradient from 60 to 100%B in 24 minutes (te/f-butylcarbamoyl-quincorine and te/f-butylquincorinylurea ligand) or 0 to 25%B in 15 minutes
  • the column contains about 0.5 g of the chromatographic material which is found to be sufficient for separating 284 ⁇ g total pDNA. All ligands according to the invention are able to separate pDNA isoforms and topoisomers confirmed by the same elution pattern, thus demonstrating the robustness of the chemoaffinity principle.
  • Example 6 Demonstration of topoisomer identity and its elution order.
  • a matrix containing an allylcarbamoyl-10, 11-dihydroquinine ligand (see Figure 2b) is synthesized according to example 1 , scheme 1 and packed in-house into 150 x 4.0 mm columns.
  • the chromatographic system and chromatographic conditions are as described in example 5, except for the gradient which was run from 10 to 60%B in 30 min.
  • Capillary gel electrophoresis is performed in a 3D CE instrument from Agilent Technologies.
  • a DB-17 coated capillary with 100 ⁇ i.d. is purchased from J&W Scientific (Folsom, CA), cut to a length of 32 cm and a detection window is made by removing the polyimide coating with a razor blade (effective length 24.5 cm).
  • the capillary is filled with Tris-borate-EDTA (TBE, 89 mM boric acid, 89 mM Tris, 2 mM EDTA, titrated to pH 9.0 with NaOH) buffer containing 0.1 % hydroxypropylmethylcellulose (HPMC, 86 kDa) purchased from Acros organics (Geel, Belgium).
  • TBE Tris-borate-EDTA
  • HPMC 0.1 % hydroxypropylmethylcellulose
  • an intercalator is added to the electrophoresis buffer [de Carmejane et al., Proceedings of SPIE-The International Society for Optical Engineering, 1999, vol. 3602, p.346-354], in this case 12 ⁇ of a 5 mg/ml aqueous chloroquine diphosphate (Fluka) solution to 4 ml of
  • electrophoresis buffer to give a final concentration of 15 ⁇ g/ml chloroquine, respectively.
  • Samples are introduced by electrokinetic injection at -5 kV for 4 seconds. Electrophoresis is then performed in negative mode at 3.3 kV for
  • Example 7 In-process control of topoisomer distribution during
  • the crude plasmid samples are directly injected into a two- dimensional HPLC system and analyzed.
  • Example 8 Cinchorine-type ligand on CIM monolith.
  • a CIM ® Epoxy Disk Monolithic Column (BIA Separations) is rinsed with a freshly prepared 2 M solution of sodium hydrogen sulfide (Sigma-Aldrich) in a mixture of methanol and 0.1 M aqueous sodium dihydrogenphosphate (Merck), (20:80, v/v) (pH 8.15) in flow through-mode with an HPLC pump for 2h. Afterwards, the column is washed with methanol/water (20:80, v/v) and then with methanol.
  • a 0.25 M solution of te/f-butylcarbamoylquincorine (structure d) is prepared by dissolving it in methanol, and ⁇ , ⁇ ' -azoisobutyronitrile (AIBN) (6 mg/ml, 0.037 M) is added as radical initiator.
  • AIBN ⁇ , ⁇ ' -azoisobutyronitrile
  • the mixture is sonicated for 5 min, filtered through a Nylon membrane, and purged with nitrogen for 10 min. Then, this tert- butylcarbamoylquincorine-solution is pumped into the thiol-functionalised CIM disc column. The column is sealed at both ends and transferred to a water bath, where the radical addition of the chromatographic ligand occurred at 60°C.
  • the column is removed from the water bath, rinsed with methanol and then equilibrated with mobile phase using an HPLC pump.
  • the separation of the plasmid isoforms is carried out using elution Method 1 (NaCI-gradient) with organic matrix, particularly suitable for preparative purposes.
  • Example 9 Modification of epoxy-group containing non-porous organic polymer particles.
  • Epoxy-modified nonporous polymethacrylate beads (epoxy-NPR, 2.5 ⁇ from Tosoh) are suspended in methanol in a three-necked round bottom flask.
  • a 2 M solution of sodium hydrogen sulfide in a mixture of methanol and 0.1 M aqueous sodium dihydrogenphosphate, (20:80, v/v) (pH 8.15) is added (10-fold molar excess related to epoxy groups) and stirred under nitrogen flow for 2h. Afterwards, the particles are filtered and washed with methanol/water (20:80, v/v) and then with methanol.
  • a 0.25 M solution of te/f-butylcarbamoylquincorine (structure d) is prepared by dissolving it in methanol, and ⁇ , ⁇ ' -azoisobutyronitrile (AIBN)
  • the particles are slurry packed into stainless steel column of the dimension 33 x 4.6 mm ID.
  • the testing of the column for the separation of the plasmid isoforms is carried out using elution Method 1 (simultaneous NaCI- and 2-propanol gradients) with organic matrix, particularly suitable for analytical purposes.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)

Abstract

The invention relates to the use of material comprising a carbamoyl-decorated anion-exchanger ligandwherein a cationic group (C), and a hydrogen donor group (N-H), are connected by a spacer with a length between 3 to 5 atoms, immobilized onto or embedded into a heterogeneous matrix, for the separation of isoforms, topoisomers, oligomeric and multimeric forms of plasmid DNA (p DNA).

Description

LIQUID PHASE SEPARATION OF PLASMID DNA ISOFORMS AND TOPOISOMERS
Technical Field
The present invention relates to the chromatographic materials and methods for separation of isoforms, topoisomers, oligomeric and multimeric forms of plasmid DNA (pDNA) governed by use of carbamoyl-decorated anion-exchange ligands immobilized or embedded into a heterogeneous matrix.
Background Art
Plasmid DNA (pDNA) is an extrachromosomal genetic unit providing its host cell with additional functionalities. Since the discovery of its great potential for use in gene therapy or genetic vaccination, much attention is paid to biotechnological production of these novel type of drugs (Schleef, M., Plasmids for Therapy and Vaccination, Wiley-VCH, Weinheim 2001). From more possible isoforms, the so- called covalently closed circular (ccc) form is considered to be most active for therapeutics. Pharmaceutical grade ccc plasmid DNA is often produced by fermentation in E.coli followed by harvesting, alkaline lysis and multi-step purification of pDNA (Urthaler, J., et al., Journal of Biotechnology, 2007, 128, pgs: 132-149). For human gene therapy, all these steps must meet regulatory guidelines. Therefore the use of animal derived compounds (e.g. enzymes like hen egg white lysozyme) and/or toxic reagents shall be avoided. Furthermore, production processes have to guarantee a low level of host-related impurities (such as endotoxines in the case of bacterial host), see in Urthaler, J., Chemical Engineering & Technology, 2005, 28, pgs: 1408-1420. Additionally, a high content of the ccc form relative to the other pDNA isoforms is recommended in the final formulation of the bioactive drug (FDA, U., in: Administration, F. a. D. (Ed.), Considerations for Plasmid DNA Vaccines for Infectious Disease Indications, Rockville, MD 2007).
There is a need for a reliable analysis of the plasmid isoform distribution during upstream and downstream processing as well as in the quality control. Apart from the ccc form, other forms need to be monitored which are considered less effective for therapy and vaccination: (a) the open circular form (oc) generated from the ccc form by a single nick in the DNA backbone, and (b) the linear form (lin) created in case when two nicks are in close vicinity. Besides these monomeric forms, also di- and oligomeric species may be generated during fermentation (Lahijani, R. et al., Human Gene Therapy, 1996, 7, pgs: 1971-1980) such as concatemers (i.e. a long continuous DNA molecule that contains multiple copies of the same DNA sequences linked in series) and catenanes (i.e. circular DNA that is interlaced together as links in a chain). The catenated DNA is attached loop to loop in contrast to the concatenated DNA which is attached end to end.
There are various methods available for the effective separation of total plasmid DNA (Stadler J., et al., J Gene Med, 2004; 6, pgs: S54-S66), e.g. thiophilic aromatic chromatography (Sandberg, L.M., et al., Journal of Biotechnology, 2004, 109, pgs: 193-199), hydrophobic interaction chromatography (Ferreira, G.N.M., et al., Pharm. Pharmacol. Commun., 1999, 5, pgs: 57-59; Diogo, M.M., et al., Journal of Chromatography A, 2005, 1069, pgs: 3-22; Tiainen P. et al., Journal of Chromatography A, 2007, 1138, pgs: 84-94; Urthaler J. et al., Chemical
Engineering and Technology, 2005, 28, pgs: 1408-1420), or peptide affinity chromatography (Han Y. and Gareth M.F., J. Chromatogr. B, 2008, 874, pgs: 21-26). In EP 1 187 840 B1 by using hydrophobic interaction chromatography (HIC) a preparative separation of two pDNA isoforms, namely ccc and oc was disclosed. However, in this case the separation is based on the non-specific (i.e. hydrophobic) interaction while suffering from the relatively low separation efficiency (e.g. on pg. 33 in Figure 7) when compared to the process according to the present invention. Furthermore, due to extremely high loads of cosmotropic salts necessary for HIC separation (e.g. on pg. 28 in Figure 1), the product solutions obtained after such loads need to be desalted accordingly, i.e. abundant salts need to be removed by use of e.g. size exclusion chromatography, dialysis or membrane separation. In addition the cumulated salts' disposal is financially very demanding. In addition, isolation of various types of nucleic acids by use of poly(L-lysine) kieselguhr chromatography was described (e.g. in Finkelstein D. B., et al., J. Biochemistry, 1972,1 1 , 25, pgs: 4853-8 ; or in Monaghan-Cannon M. and Dunican L. K., The Biochemical Journal, 1969, 115, 3, 7P). Furthermore, amino acid (Arg, His, Lys) affinity chromatographic separations were disclosed (a) for analytical use in Sousa A., et al., J. Sep. Sci. 2010, 33, pgs: 2610-2618, and (b) for preparative purposes in Sousa F., et al., Trends in Biotechnology, Vol.26 No.9, 2008, pgs:518-525. Recently, a 16-mer peptide with the sequence NH2-Cys-Met- Lys-Tyr-Val-Ser-His-Gly-Thr-Val-Ser-Arg-Val-Val-Asn-Gln-COOH bound to polymethacrylate monolith was reported to show binding to pDNA and selectivity for some isoforms in Y. Han, et al., J. Chromatogr. B, 2008,874, pgs: 21-26.
Native samples of ccc plasmids consist of a series of individual topological isomers (topoisomers), which differ by various degrees of supercoiling. These ccc topoisomers have different linking numbers, thus a different number of
superhelical turns (Depew, R. E., Wang, J. C, Proc. Natl. Acad. Sci. U. S. A., 1975, 72, pgs: 4275-4279). Supercoiling consists of two quantities, twist (Tw) and writhe (Wr), which are interconvertible but for a certain topoisomer the sum of both is invariant. Bacterial plasmids, a key element in biotechnology, molecular biology and the development of novel biopharmaceuticals and therapeutics, are negatively supercoiled in vivo. The amount of supercoiling is around 6%, meaning that on average 6 negative supercoils are introduced per 100 helical turns of the most common type of DNA, so called B-DNA, under standard conditions, corresponding to 6 negative supercoils per 1050 base pairs on average (if the standardized value of 10.5 base pairs per turn is used for the calculation). The topoisomer pattern was found to be changed during bacterial cells proliferation, in vivo according to a circadian rhythm (Woelfle, M.A., PNAS, 2007, 104, 47, pgs: 18819-18824). Concerning the methods of the plasmid topoisomer separation, there are available various gel-based electrophoretic methods including a capillary gel electrophoresis with the highest resolving power (Schmidt, T., et al., Analytical Biochemistry, 1999, 274, pgs: 235-240), however suffering overall from a low robustness, the low sample salt-tolerance and high time-consumption. The prerequisite of DNA intercalating agent might cause unwanted toxicity within this procedure. Therefore, liquid chromatography based methods are preferred both for analytical and preparative applications. A large number of different chromatographic applications and different chromatographic supports are available for the preparative plasmid purification of various quality preferences (e.g. Diogo, M. M., et al., Journal of Chromatography, A 2005, 1069, pgs: 3-22; Wu, L, Pang, G.-c, Chromatographia 2007, 66, pgs: 151-157; Tiainen, P. et al., Journal of Chromatography, A 2007, 1 149, pgs: 158-168; Sousa, F. et al., Analytical Biochemistry 2005, 343, pgs: 183-185; or Urthaler, J., et al., Journal of Chromatography, A 2005, 1065, pgs: 93-106). However, in the analytical scale the choice is limited to anion exchange columns, such as the DNA-NPR from Tosoh Bioscience (Tosoh
Corporation, Tokyo, Japan) or GenPak FAX from Waters (Waters Corporation, Milford, Massachusetts, USA), employing the same basis material, i.e. non-porous 2.5 μηι particles composed of a hydrophilic organic polymer with diethylaminoethyl (DEAE)-based ligands. Topoisomer distribution can be analyzed so far by electrophoretic techniques only. Apart from that, there are neither materials nor methods (including chromatography) available in the state of the art for the separation of this type of ccc plasmid DNA.
Generally, the effectiveness of any chromatographic method mainly depends on three essentials: (1) a length of separation compartment, e.g. column filled with chromatographic material, (2) retention factor (capacity factor) describing the migration rate of an analyte on a column, and (3) selectivity representing ratio between the retention factors of two species which are to be separated. The most impact of those has the latter one, wherein the selectivity is influenced by characteristics of supportive material (also known as solid phase/ matrix/ support) and of the nature of the ligand attached to or embedded into the support.
Porous supports with mid-sized pores (mesopores) used for small molecules do not allow the biomolecules to enter inside (Rozing, G. P., Journal of
Chromatography A, 1989, 476, pgs: 3-19). Large and gigaporous materials suffer from slow mass transport and low sample recovery. The most promising option in the art for use in analytics are considered to be micropellicular stationary phases characterized by a thin retentive layer at the surface of a non-porous particle (Huber, C. G., Journal of Chromatography, A, 1998, 806, pgs: 3-30). Another alternative (particular suitable for preparative uses) represent monoliths due to their excellent binding capacities and ultra-short analysis with benefits of high resolution at fast column flow and no mass transfer limitation (Hahn, R., et. al., Separation Science and Technology, 2002, 37, pgs: 1545-1565).
In the state of the art less attention is given to the ligands employed in ion exchange chromatography for plasmid separation, wherein simple tertiary (such as DEAE, diethylaminoethyl) or quaternary (often abbreviated with Q) amines are used as a standard. These rather unspecific groups separate nucleic acids according to the number of negative charges of the analyte (Wieder, W., et al., Journal of Separation Science, 2006, 29, pgs: 2478-2484) resulting in relatively insufficient separation. Since the separation, which is highly relevant both for analytical and preparative approach, depends on charge density and
hydrodynamic factors (Onishi, Y., et al, Analytical Biochemistry, 1993, 210, pgs: 63-68) effects similar to slalom chromatography (i.e. wherein the progression of the DNA molecules through the closed column follows the flow direction and is like a snake edging, so called "reptation") can be observed. In this approach the pDNA isomer separation is dependent on the flow-rate and gradient slope (Smith, C. R., et al., Journal of Chromatography, B: Analytical Technologies in the
Biomedical and Life Sciences, 2007, 854, pgs: 121-127) causing this system to be less robust and more unpredictable. Furthermore, Molloy et al., Nucleic Acid Research, 2004, 32, e129/121-e129/110 point out certain drawbacks of plasmid separation by using ion exchange chromatography based on DEAE ligands, wherein the calculated content of the oc isoform (impurity) in the ccc pDNA sample was significantly lower compared to the application of agarose gel electrophoresis.
Various cinchonan alkaloid ligands including cinchonan carbamates and cinchonan ureas were disclosed as chiral catalysts in asymmetric organic synthesis (WO92/20677 and US6197994B1), and as chiral discriminants (i.e. chiral selectors) in analytical chemistry (Laemmerhofer M., et al., Journal of Chromatography, A 1996, 741 , pgs: 33-48; W097/46557; US6616825 B1 ;
Lee Y.-K. et al., Polymer 43, 2002, pgs: 7539-7547). In addition, amino acid (arginine, lysine and histidine) ligand structures have been currently described in Sousa F., Queiroz J.A., J of Chromatography A,doi: 10.1016/j.chroma.2010.11.002 (in press) and Sousa A, et al., J. Sep. Sci. 2010, 33, pgs: 2610-2618, for the separation of oc and ccc pDNA isoforms in the analytical scale. Overall, sufficiently robust, predictable, reliable and accurate methods and/or materials for the effective separation of all three pDNA isoforms (ccc, oc, and lin) by use of chromatography (including affinity chromatography) both in preparative and analytical scale are not available in the state of the art. Summary of the Invention
The invention relates to use of a material comprising a ligand according to formula 1
Figure imgf000007_0001
wherein the ligand contains a cationic group (C) and a hydrogen donor group (N-H) connected by a spacer with a length between 3 to 5 atoms,
m, o and r are independently from one another either 0 or 1 , and
k, I, n and p are independently from one another either 0, 1 or 2, and
Y is any moiety selected from the group -CH2-, -0-, -NH- or -S-,
Z is any moiety selected from the group -C-, -S-, or -P- , and
RL R2 and R3 are anyone of the substituents from the group consisting of hydrogen, CMS branched or unbranched alkyl, C2-is branched or unbranched alkenyl, C2-is branched or unbranched alkynyl, C3.n-carbocycle , C3.8-heterocycle , C5.i8-aryl and C5.i3-heteroaryl,
wherein R^ R2 and R3 optionally comprise independently from one another one or more moieties selected from the group -S-, -0-, -NH-, and
each of R^ R2, R3 can be optionally and independently substituted with one or more substituents selected from the group consisting of hydrogen, Ci_6 branched or unbranched alkyl, C2.6 branched or unbranched alkenyl, C2.6 branched or unbranched alkynyl, C3.8-carbocycle , C3.8-heterocycle and C5.i0-aryl, C5.i0- heteroaryl, and
whereby the cationic group C is a C3_n heterocycle comprising at least one nitrogen atom and optionally another heteroatom selected from the group consisting of sulphur, oxygen, nitrogen and phosphorus, or C5-i8 heteroaryl comprising at least one nitrogen atom and optionally another heteroatom selected from the group consisting of sulphur, oxygen, nitrogen and phosphorus, or
branched or unbranched CM0 alkyl, branched or unbranched C2-io alkenyl, branched or unbranched C2-io alkynyl comprising at least one nitrogen atom and optionally another heteroatom selected from the group consisting of sulphur, oxygen, nitrogen and phosphorus, wherein C and R3 or C and R2 are optionally linked to each other by forming a ring, and
wherein the ligand is optionally immobilized onto or embedded into a matrix via or R3 group,
for the separation of plasmid DNA isoforms or topoisomers.
Still further, the invention relates to the methods for separation of plasmid DNA isoforms including covalently closed circular (ccc), open circular (oc) and linear (lin) forms, oligomeric and multimeric forms such as monomers, dimers, trimers, tetramers, oligomers, multimers, and/or ccc topoisomers by using of the materials according to the invention.
Detailed Description of the Invention
It has now unexpectedly been found that a material according to the invention comprising a carbamoyl-decorated anion exchange ligand immobilized or embedded into a heterogeneous matrix can be used for the separation of isoforms, topoisomers, oligomeric and multimeric forms of plasmid DNA (pDNA).
In its broadest aspect, the invention provides a material which comprises a ligand according to formula 1
Figure imgf000008_0001
wherein the ligand contains a cationic group (C) and a hydrogen donor group (N-H) connected by a spacer with a length between 3 to 5 atoms,
m, o and r are independently from one another either 0 or 1 , and
k, I, n and p are independently from one another either 0, 1 or 2, and
Y is any moiety selected from the group -CH2-, -0-, -NH- or -S-,
Z is any moiety selected from the group -C-, -S-, or -P- , and
RL R2 and R3 are anyone of the substituents from the group consisting of hydrogen, CMS branched or unbranched alkyl, C2-is branched or unbranched alkenyl, C2-is branched or unbranched alkynyl, C3.n-carbocycle , C3.8-heterocycle , C5.i8-aryl and C5.i3-heteroaryl,
wherein R^ R2 and R3 optionally comprise independently from one another one or more moieties selected from the group -S-, -0-, -NH-, and
each of R^ R2, R3 can be optionally and independently substituted with one or more substituents selected from the group consisting of hydrogen, Ci_6 branched or unbranched alkyl, C2.6 branched or unbranched alkenyl, C2.6 branched or unbranched alkynyl, C3.8-carbocycle , C3.8-heterocycle and C5.i0-aryl, C5.i0- heteroaryl, and
whereby the cationic group C is a C3_n heterocycle comprising at least one nitrogen atom and optionally another heteroatom selected from the group consisting of sulphur, oxygen, nitrogen and phosphorus, or
C5.i8 heteroaryl comprising at least one nitrogen atom and optionally another heteroatom selected from the group consisting of sulphur, oxygen, nitrogen and phosphorus, or
branched or unbranched CM0 alkyl, branched or unbranched C2_i0 alkenyl, branched or unbranched C2_i0 alkynyl comprising at least one nitrogen atom and optionally another heteroatom selected from the group consisting of sulphur, oxygen, nitrogen and phosphorus, wherein C and R3 or C and R2 are optionally linked to each other by forming a ring, and
wherein the ligand is optionally immobilized onto or embedded into a matrix via or R3 group,
for the separation of plasmid DNA isoforms or topoisomers. One of further preferred embodiments represents the material according to formula 2
Figure imgf000010_0001
wherein NA represents the nitrogen atom of the cationic group,
NB-H the hydrogen donor (located adjacent to a carbonyl C=0),
Y is an oxygen (-0-) thus yielding a carbamate group or
an (-NH-) thus yielding a urea group, and
RL R2, R3 are anyone of the substituents selected from the group consisting of hydrogen, CMS branched or unbranched alkyl, C2-is branched or unbranched alkenyl, C2-is branched or unbranched alkynyl, C3.n-carbocycle , C3.8-heterocycle , C5.i 8-aryl and C5.i3-heteroaryl,
wherein R^ R2 and R3 optionally comprise independently from one another one or more moieties selected from the group -S-, -0-, -NH-, and
wherein R^ R2 and R3 can be optionally and independently substituted with one or more substituents selected from the group consisting of hydrogen, Ci_6 branched or unbranched alkyl, C2.6 branched or unbranched alkenyl, C2.6 branched or unbranched alkynyl, C3.8-carbocycle , C3.8-heterocycle and C5.i0-aryl, C5.10- heteroaryl, and
wherein the substitution optionally comprises the anchoring to a matrix via or for the separation of plasmid DNA or topoisomers. In one of the most preferred embodiments according to formula 2, Y= -0-, Ri is alkyl immobilized to silica or thiolpropyl-modified silica, R2 is methoxyquinoline and R3 is ethyl or vinyl. The term "material" according to the invention refers to and comprises a carbamoyl-decorated anion exchange type of ligands optionally immobilized onto or embedded into a heterogeneous (solid or liquid) matrix such as a
chromatographic support, substrate, membrane or liquid phase.
The term "carbamoyl" within the meaning of the present invention refers to a moiety selected from a group of -0-C(=0)-NH-, -C(=0)-NH-, -C(=0)-NH2, or which may also be part of a urea -NH-C(=0)-NH-or carbazide -NH-NH-C(=0)-NH-. Carbamoyl in the meaning of the present invention does not preclude other isosteric functional groups consisting of a hydrogen-donor acceptor system such as sulphonamide, phosphonamide and similar functionalities, as defined by the formula 2. The term "ligand" according to the invention refers to and comprises a chemical structure, which is bound via a linker or embedded into a matrix and is able to interact with plasmid DNA. The preferred embodiment of the ligand is quincorine- or quincoridine carbamate, or quincorine- or quincoridine urea. In context of the use for the separation of plasmid DNA isoforms, topoisomers, oligomeric and multimeric forms one of the more preferred embodiments is cinchonan carbamate or cinchonan urea, most preferred is quinine- or quinidine carbamate, in particular propyl carbamoyl quinine or quinidine, te/f-butylcarbamoyl-quinine or quinidine, and allylcarbamoyl-10, 11-dihydroquinine or quinidine. The term "optionally substituted" is intended to mean that a hydrogen atom of a methylene group or a hydrogen atom of an aromatic or heteroaromatic ring is substituted with a different organic or inorganic substituent.
The term "Ci-i8-alkyl" herein means a saturated branched or unbranched hydrocarbon chain of 1-18 carbon atoms.
The term "Ci-6-alkyl" herein means a saturated branched or unbranched hydrocarbon chain of 1-6 carbon atoms. The term "C2.i8-alkeny herein means an unsaturated branched or unbranched hydrocarbon chain of 2-18 carbon atoms, which comprises at least one double bond.
The term "C2-6-alkenyl" herein means an unsaturated branched or unbranched hydrocarbon chain of 2-6 carbon atoms, which comprises at least one double bond.
The term "C2.i8-alkyny is intended to mean an unsaturated branched or unbranched hydrocarbon chain of 2-18 carbon atoms, which comprises at least one triple bond.
The term "C2-6-alkynyl" herein is an unsaturated branched or unbranched hydrocarbon chain of 2-6 carbon atoms, which comprises at least one triple bond. The term "branched " is intended to mean that at least one atom of the hydrocarbon chain, optionally comprising a chain atom is selected from sulphur, oxygen or nitrogen, is covalently bound to another chain atom.
The term "unbranched is intended to mean that any atom of the hydrocarbon chain, optionally comprising a chain atomis selected from sulphur, oxygen or nitrogen, is not covalently bound to any other chain atom.
The term "chain atom" within the meaning of the present invention relates to an atom that exhibits two separate bonds, such as carbon, sulphur, oxygen or nitrogen.
The term "C3-n-carbocycle" is intended to mean an aliphatic hydrocarbon 3-11 carbon ring atoms. The term "C3.8-carbocycle" is intended to mean an aliphatic hydrocarbon 3-8 carbon ring atoms.
The term "C3.8-heterocycle" is a carbocycle comprising 3-8 ring atoms, where at least one of the ring atoms is not carbon but an atom selected from N, O, or S. The term "C5-i8-ary is an aromatic hydrocarbon ring with 5-18 ring atoms.
The term "C5.io-aryl" is an aromatic hydrocarbon ring with 5-10 ring atoms. The term "C5.i 3-heteroaryl" is an aromatic ring with 5-13 ring atoms, wherein at least one ring atom is not carbon but an atom selected from N, O or S.
The term "C5.io-heteroaryl" is an aromatic ring with 5-10 ring atoms, wherein at least one ring atom is not carbon but an atom selected from N, O or S.
In one of the preferred embodiments is anyone of the substituents from the group consisting of hydrogen, Ci_8 branched or unbranched alkyl, C2.8 branched or unbranched alkenyl and C2.8 branched or unbranched alkynyl, optionally comprising one or more sulphur atoms.
In another preferred embodiment is anyone of the substituents from the group consisting of C3.8-carbocycle, C5.8-heterocycle and C5.i0-aryl, C5.9-heteroaryl.
In still further preferred embodiment R3 is anyone of the substituents selected from the group consisting of hydrogen, Ci_8 branched or unbranched alkyl, C2.8 branched or unbranched alkenyl and C2.8 branched or unbranched alkynyl, optionally comprising one or more sulphur atroms.
In another preferred embodiment R2 is anyone of the substituents selected from the group consisting of hydrogen, C5.i0-aryl and C5.9-heteroaryl.
In one of the most preferred embodiments according to formula 1 , o = 0 and m = 1 , or o = 1 and m = 0. In still further preferred embodiments according to formula 1 , o = 0 and m = 1 , and k = 1 and I = 1 , Z is -C- and n = 1. Alternatively, in another most preferred embodiment o = 1 and m = 0, and k = 1 and I = 1 , Z is -C- and p = 1.
In further preferred embodiments according to formula 1 , o = 0 and m = 1 , and k = 1 and I = 1 , Z is -S- and n = 2. In still preferred embodiment according to formula 1 , o = 1 and m = 0, k = 1 and I = 1 , Z is -S- and p = 2. The term "anchoring to a matrix" is intended to mean any substituent that forms a stable connection between the ligand and the matrix or between the ligand and residues that are attached to the matrix.
The term "molecular weight" according to the invention refers to the sum of the relative atomic masses of the constituent atoms of the ligand according to the invention. In a preferred embodiment the molecular weight of the ligand is between 200 to 2000Da, more preferably between 250 to 1200Da, most preferably between 400 to 700 Da. The "cationic group C" is a C3.n heterocycle comprising at least one nitrogen atom and optionally another heteroatom selected from the group consisting of sulphur, oxygen, nitrogen and phosphorus, or
C5.i8 heteroaryl comprising at least one nitrogen atom and optionally another heteroatom selected from the group consisting of sulphur, oxygen, nitrogen and phosphorus, or
branched or unbranched CM0 alkyl, branched or unbranched C2-io alkenyl, branched or unbranched C2-io alkynyl comprising at least one nitrogen atom and optionally another heteroatom selected from the group consisting of sulphur, oxygen, nitrogen and phosphorus,
wherein C and R3 or C and R2 are optionalloy linked to each other by forming a ring.
The term "ring" within the meaning of the invention refers to mono-, bi-, polycyclic or spirocyclic rings.
In a further preferred embodiment the cationic group is incorporated into a cyclic or bicyclic ring system.
In a preferred embodiment the bicyclic ring system is tropane, (hydro)quinolizidine, (hydro)pyrrolizidine, 1-aza-adamantane, azabicyclo[3.2.1]octane, azabicyclo[3.2.1]nonane, azabicyclo[3.3.1]nonane, (hydro)indolizidine,
(hydro)benzimidazol, (hydro)quinoline, (hydro)isoquinoline, more preferred azabicyclo[4.4.0]decane, most preferred quinuclidine. The term "cationic group" within the meaning of the present invention further refers to a moiety containing one nitrogen atom bearing a partial or permanent positive charge selected from a group consisting of tertiary-, quaternary-, secondary-, primary amine or guanidine, amidine and (hetero)aromatic amino group.
A preferred embodiment of the cationic group represents aliphatic amine, more preferred quaternary amine, most preferred tertiary amine. In one of the most preffered embodiments the teriary amine is a part of quinuclidine.
The term "hydrogen donor moiety" refers to a combination of a hydrogen atom bound to an electronegative atom such as nitrogen, oxygen or fluorine. The term "hydrogen acceptor group" refers to an electronegative atom such as oxygen, nitrogen, fluorine or sulphur with at least one free electron pair.
The term "spacer" within the meaning of the present invention refers to a group of adjacent atoms of a specified number being bound on either side to functionally important entities, namely a cationic group (C) on one side and a hydrogen donor moiety (N-H) on the other side. The number of adjacent atoms is counted as a shortest distance through an atom chain. The length of the spacer is between 3 and 5 atoms. In the most preferred embodiment the length of the spacer is equal to 4 atoms.
In another more preferred embodiment the ligand according to the invention is located not further than 6 atoms from the matrix.
The term "immobilized" within the meaning of the present invention refers to a covalent bonding onto a solid or liquid matrix (support).
The term "embedded" within the meaning of the present invention refers to a non- covalent inclusion into the solid or liquid matrix (support). The term "anchoring to a matrix" is intended to mean any substituent that forms a stable connection between the ligand and the matrix or between the ligand and residues that are attached to the matrix. The term "heterogeneous matrix" within the meaning of the present invention relates to a matrix (support) that cannot be unified with the solvent containing dissolved plasmid DNA being either insoluble or immiscible.
The term "plasmid DNA" refers to an extrachromosomal genetic unit consisting of double stranded deoxyribonucleic acid.
The term "isoforms" within the meaning of the present invention refers to the different forms of plasmid DNA of equal molecular weight selected from the group of covalently closed circular (ccc), open circular (oc) and linear (lin) plasmid. The associated analysis of such isoforms should be denoted as isoform analysis.
The terms "oligomeric and multimeric" within the meaning of the present invention relate to different forms of plasmid DNA of different molecular weight originating from the combination of monomeric isoforms into a larger molecule, the molecular weight of which is an integral multiple of that of the monomer. Subsequently, the term oligomeric marks combinations of two, three or four monomers, while the term multimeric marks combinations of five and more monomers. The oligomeric and multimeric combinations may be either in form of catenane or concatemer. The term "catenane" according to the invention refers to circular DNA that is interlaced together as links in a chain.
The term "concatemer" according to the invention refers to long continuous DNA molecule that contains multiple copies of the same DNA sequences linked in series.
The terms "catenane" and "concatemer" are characterized in that catenated DNA is attached loop to loop in contrast to concatenated DNA which is attached end to end. The term "topoisomers" within the meaning of the present invention refers to a covalently closed circular (ccc) plasmid DNA molecules with a different degree of supercoiling, described by the topological linking number or linking number difference. Topoisomers of one individual plasmid have equal molecular weight and connectivity. The associated analysis of such topoisomers should be denoted as topology analysis or topoisomer analysis.
The term "separation" within the meaning of the present invention relates to a segregation of different forms of plasmid DNA such as isoforms, topoisomers, oligomeric and multimeric forms based on different affinities of these forms to the ligand (referred to as chemoaffinity principle).
The term "chromatography" refers to a set of separation techniques employing two heterogeneous phases, while one phase, the so called mobile phase, is moving along the other phase, the so called stationary phase.
Preferred embodiment is the material according to the invention wherein the hydrogen donor N-H is located adjacent to a hydrogen acceptor group. The term "adjacent" in the meaning of the present invention denotes a direct connection between two atoms or atom groups by a single covalent bond.
In the preferred embodiment the hydrogen acceptor is selected from carbonyl (C=0), sulfonyl (S02) and phosphonyl group (P=0).
In still further preferred embodiment the hydrogen acceptor and hydrogen donor group form part of amide, carbamate, urea, phosphonamide or sulphonamide group. In further preferred embodiment the plasmid DNA comprises mixtures of any components selected from the group consisting of ccc and its topoisomers, oc, lin, dimer, trimer, tetramer, oligomer, multimer (in form of catenane or concatemer) independent from the size of the plasmid and its nucleotide sequence. Within the meaning of the present invention the term "matrix" encompasses a solid support capable of attaching a ligand, or a liquid capable of dissolving the ligand. The term "solid matrix" within the meaning of the present invention refers to a solid support suitable for the desired chromatographic separation or liquid-solid extraction, selected from a group of inorganic polymers or organic polymers, preferably micropelicullar silica-based particles.
The term "micropelicullar" refers to a non-porous matrix particle which is characterized by a core of fluid-impervious support material (fused-silica particles or organic polymer microspheres) covered by a thin, retentive layer of stationary phase. The thin retentive layer of stationary phase can be obtained by roughening the surface and attaching the respective chromatographic ligand to obtain an adsorption surface that can retain the target solutes.
The term "liquid matrix" refers to a liquid selected from a group of apolar solvents such as alkanes, cycloalkanes, or polymeric liquids such as polysiloxanes, polyethyleneoxides, or a polymeric liquid such as polysiloxane or polyethylenoxide diluted in another solvent.
In a preferred embodiment the matrix according to the invention is selected from organic or inorganic polymers.
The term "organic polymers" refers to a solid organic polymer such as
poly(meth)acrylate and its copolymers, polystyrene and its copolymers, poly(meth)acrylamide and its copolymers, ring-opening methathesis polymers, polysaccharides and its copolymers such as agarose, and bears chemical groups at the polymer surface capable of a covalent attachment of a spacer and/or a ligand.
The term "inorganic polymers" refers to a solid inorganic polymer such as silicon oxide (silica), titanium oxide, germanium oxide, zirconium oxide, aluminium oxide and glass. The polymer surface is capable of a covalent attachment of a spacer and/or a ligand.
In still further preferred embodiment the solid matrix is a particle, a monolith resin, a membrane, or a magnetic bead. The term "particle" refers to a solid matrix structure of various sizes and morphological features including but not limited to irregular, regular, spherical, porous, non-porous, micropellicular. Usually there is a large number (> 1000) of individual particles within one separation compartment.
The term "monolith resin" refers to a solid matrix structure containing flow-through channels allowing for convective flow, also called macropores, optionally containing smaller-sized pores additionally such as mesopores and micropores. Usually there is a single piece or only a small number (< 10) of individual monolith resins in one separation compartment.
The term "membrane" refers to a solid matrix in the shape of a thin layer being permeable for the solvent and semi-permeable for the solutes include the sample components. The membrane is selected from the group of polysaccharides such as cellulose, cellulose ester, poly(meth)acrylates, poly(styrenes),
polytetrafluoroethylene, polysulfone, polyacrylonitril, polyphenylenoxide, polyethylene, polyropylen, teflon, polyethyleneterephthalate, polyvinylidenchlonde, PVC, polyimide, PVA, polycarbonate.
The term "magnetic bead" refers to a particle composed of a magnetic or ferromagnetic inner core and an outer solid matrix shell, which is attracted when a magnetic field is applied. The preferred embodiment of the material according to the invention is selected from a group consisting of:
(structure a)
Figure imgf000019_0001
3-(allylcarbamoyloxy)-/\/-benzylpiperidine immobilized onto 3-mercaptopropylsilica matrix
Figure imgf000020_0001
The substructure on the left hand side represents the supporting matrix and the substructure on the right hand side of the dotted line represents the ligand.
Figure imgf000020_0002
triethoxysilyl-activated propylcarbamoylquinine-ligand immobilized onto a bare silica matrix
Figure imgf000020_0003
The substructure on the left hand side represents the supporting matrix and the substructure on the right hand side of the dotted line represents the ligand.
(structure c)
Figure imgf000021_0001
The substructure on the left hand side represents the supporting matrix and the substructure on the right hand side of the dotted line represents the ligand.
Figure imgf000022_0001
O-te/f-butylcarbamoyl-quincorine immobilized onto 3-mercaptopropyl-modified silica matrix
Figure imgf000022_0002
The substructure on the right hand side represents the supporting matrix and the substructure on the left hand side of the dotted line represents the ligand.
Figure imgf000023_0001
te/f-butylquincorinyl-urea ligand immobilized onto a 3-mercaptopropyl-modified silica matrix
Figure imgf000023_0002
The substructure on the right hand side represents the supporting matrix and the substructure on the left hand side of the dotted line represents the ligand. (structure f)
Figure imgf000024_0001
te/f-butylcarbamoyl-quinine immobilized onto mercaptopropyl-modified silica matrix
Figure imgf000024_0002
Figure imgf000025_0001
te/f-butylcarbamoyl-quinine ligand immobilized onto thiol-modified
polymethacrylate beads (Suprema-Gel 30u)
Figure imgf000025_0002
The substructure on the right hand side represents the supporting matrix and the substructure on the left hand side of the dotted line represents the ligand. The separation of all three pDNA isoforms or topoisomers is governed by the material comprising carbamoyl-decorated anion-exchange ligands, which have not been employed so far for this type of liquid phase separation. These ligands according to the invention comprise a well defined arrangement of a NH-donor, H-acceptor, and the anion exchange site. Hence the plasmid isoforms/
topoisomers interaction with the material comprising the ligand(s) is directed in a defined way, ensuring an invariant elution order. Thus, the present invention claims a new reliable and predictable concept for separation of very large biomolecules based on chemoaffinity principles. Furthermore, the ccc topoisomers have a potential to represent an additional quality control parameter in the biotechnological production including the final product characterization.
It will be apparent to those skilled in the art that various modifications can be made to the materials, methods and processes of this invention. Thus, it is intended that the present invention covers such modifications and variations, provided they come within the scope of the appended claims and their equivalents. All publications cited herein are incorporated in their entireties by reference.
Chromatographic ligands suitable for plasmid DNA separation are designed in order to make an easy attachment to the matrix possible (Example 1), wherein a ligand containing a terminal alkene group reacts with a thiol group in a radical addition reaction. Thus, in a first step a linker is attached to the matrix containing a terminal thiol group. In a second step, the matrix and the alkene-containing ligand are mixed in the presence of a radical initiator to give a stable thio-ether bond between the ligand and the linker bound to a matrix (see structure a). Using this process, stable chromatographic materials are easily obtained with a high ligand coverage on the matrix surface.
To practically assess the role of the materials according to the invention two of quinine-carbamate ligands, namely propylcarbamoylquinine and allylcarbamoyl- 10,1 1-dihydroquinine, are employed for the chromatographic analytical separation of plasmid pMCP1 (Boehringer Ingelheim, size 4.9 kb). The first one is anchored via a short propyl-linker between the ligand and the silica matrix (4 bonds between the first silicon atom of the matrix and the NH hydrogen donor, see structure b), and the other one via a long linker (8 bonds between the first silicon atom of the matrix and the NH hydrogen donor, see structure c) to the thiopropyl-modified silica matrix. Comparison of the chromatographic properties of the long linker and the short linker disclose that the recovery of the oc form is significantly improved by use of the short-linked ligand (i.e. full recovery equal to 1 μg of the 4.9 kb plasmid is recorded during one chromatographic run as shown in Example 2). The main difference is the length of the linker (3 atoms versus 7 atoms), i.e. the distance between the ligand and the surface of the matrix is not identical. Using the material containing the short linker complete recoveries of all isoforms including the oc form are found due to proximity of negatively charged remaining silanols which have a repulsing effect on pDNA. Furthermore, these data show overall improvement (superiority) of the material properties in terms of resolution between oc and ccc form as well as in terms of oc recovery of the material when compared to the commercially available columns currently used for pDNA isoform analysis.
To test the impact of the morphology of the matrix, the long-linked ligand described in the previous paragraph is attached via the long linker to the following silica-based matrixes: 1.5 μηι non-porous particles, 10 μηι porous particles and a monolith (Example 3). Columns containing these materials are tested in the analogical experimental setup as disclosed in the previous paragraph. Here, the samples containing all three isoforms of pDNA (oc, ccc and lin isoforms of the pMCP1 plasmid) are loaded onto the columns and eluted from the column under identical conditions. Substantial differences are observed between these solid supports. All tested matrixes are suitable for separating the ccc isoform from the oc isoform and for separating the ccc isoform from the lin isoform. Additionally, when using the 1.5 μηι matrix, an efficient separation between the oc and linear isoforms is achieved (see in Figure 1 a). Thus, for analytical purposes the 1.5 μηι support is the preferred choice. However, the 10 μηι porous matrix (see Figure 1 b) and the monolithic support (see Figure 1 c) both are suitable for preparative applications focusing merely on the separation of ccc form. In spite of the coelution of the oc and lin isoforms, still effective separation of the ccc form is achieved in this case.
Concerning the topoisomer separation, chromatographic selectivity calculated as retention time difference between the highest abundant topoisomers is found to be equal (0.12 ± 0.02) on all tested supports. This shows the importance of the chemoaffinity separation principle resulting in high robustness of the separation. However, the 1.5 μηι matrix provides the highest separation efficiency due to small peak width and is thus the preferred choice for analytical purposes.
In general, it was found that small non-porous spherical particles provide best separation efficiencies for pDNA isoforms and topoisomers and are thus most suitable for analytical scale separation. Large porous particles and monoliths still provide good separation of pDNA forms, especially when separating the ccc isoform from the oc and linear isoforms. Due to their low pressure drops and higher binding capacities, especially inherent to monoliths, they are more suitable for preparative applications.
Furthermore, Example 4 compares two different methods for pDNA separation, namely Method 1 by using of the increasing gradient of sodium chloride (NaCI) and Method 2 with the increasing pH gradient. In both cases a chromatographic column containing the material based on 1.5 μηι non-porous particles
(structure b), is applied for pDNA separation. Significant differences are found between these two analytical methods for pDNA characterization.
During analysis using Method 1 with a combined gradient of NaCI and of
2-propanol for the elution of the bound pDNA, the mobile phase concentration of both, NaCI and 2-propanol increases simultaneously. In this case the oc, the linear and the individual ccc topoisomers are all separated during a single
chromatographic run (see Figure 1a).
During analysis using Method 2 with a combined gradient of pH and of 2-propanol for the elution of the bound pDNA, the pH value of the mobile phase concentration and its 2-propanol contents increase simultaneously. In this case a separation of all three isoforms (oc, ccc and linear) is achieved (see Figure 2a), however lacking the separation of the individual topoisomers. Since the ccc isoform is eluted as a single peak, the separation of the other two forms is further improved compared to NaCI-mediated elution. Additionally, when 1 μg of each isoform is loaded onto a 50 x 4.6 mm column, full recoveries of all isoforms (oc, lin and ccc) in the whole range of tested plasmid sizes, namely 4.9 kb and especially 9.9 kb and 14.5 kb) are found (i.e. the separation of large-sized pDNA separation is superior when compared to the known techniques such as ion exchange chromatography).
Therefore, Method 2 is preferred for the analytical determination of the plasmid homogeneity, i.e. the content of the ccc form relatively to the other forms (oc and lin), independent on the size of the plasmid, as well as for preparative application for isolation of ccc pDNA (without topoisomer separation), due to its narrow peak form compared to NaCI-mediated elution and lower salt loads of the collected fractions.
To demonstrate the variability of ligands to be used for pDNA isoform and topoisomer separation, three different ligands are attached to 5 μηι spherical silica particles, namely te/f-butylcarbamoyl-quincorine (structure d) and tert- butylquincorinyl-urea (structure e), both attached via a long linker, and
propylcarbamoylquinine attached directly (structure b) to the support (Example 5). The ccc pDNA sample containing about 5% of the oc isoform is loaded onto each of these columns and eluted under identical conditions employing a linear gradient of sodium chloride and 2-propanol. Figure 3a shows a chromatographic separation of such pDNA sample employing a te/f-butylquincorinyl-urea ligand and Figure 3b shows such separation employing a te/f-butylcarbamoyl-quincorine ligand, while in Figure 4a (continuous line) such separation is shown employing a
propylcarbamoylquinine ligand. On all these columns, a comparable elution pattern (equal elution order) is obtained demonstrating the robustness of the chemoaffinity principle. Firstly, the oc isoform elutes from the column, after which the so called Boltzmann-distributed pattern of ccc topoisomers is obtained (i.e. relative concentrations of each individual species according to their free energy; probability measure for the distribution of the states of a system according to the energy). Such a novel and robust separation, especially of plasmid topoisomers, represents a major invention for the use of plasmid DNA and depicts a significant advantage for both, analytical and preparative scale applications.
In order to demonstrate the loading capacity of the material, a total pDNA amount of 284 μg is loaded onto a 50 x 4.6 mm column containing 1.5 μηι non-porous silica support with a propylcarbamoylquinine ligand. For this experiment the maximum injection volume of the HPLC system is employed. Upon elution with a combined salt and 2-propanol gradient, a chromatogram is obtained as shown in Figure 3c. No overloading effects and no reduction of the chromatographic resolution between the individual topoisomer peaks are observed. Thus, by use of a single analytical column of such small dimensions, milligram quantities of an individual topoisomer can easily be isolated after approximately 30 to 50 runs. Furthermore, chromatography in general is characterized by the linear scalability, thus larger-scale preparative applications can be set up following general rules for chromatographic upscaling.
The elution pattern of topoisomers is assessed by analyzing the eluted fractions using a complementary method, capillary gel electrophoresis (Example 6). During the elution of individual topoisomers, it is found that those which are being less negatively supercoiled elute firstly. Accordingly, topoisomers with a higher negative supercoiling elute later, shown by separating the isolated
chromatographic fractions "A" and "B from the chromatogram in Figure 4a (dashed lines) by chloroquine-containing capillary gel electrophoresis (Figure 4b). The less supercoiled topoisomer, in this example topoisomer "A", has also lower writhe, thus the molecule is of bigger size than the more supercoiled topoisomer "B. Since the gel electrophoresis separation is size-dependent, the topoisomer "B migrates faster than the topoisomer "A", and the relaxed oc isoform is the slowest migrating species in the sample. The topoisomer patterns for the pMCP1 plasmid (4.9 kbp) following the Boltzmann distribution, are also recorded employing the column containing a propylcarbamoylquinine ligand by analyzing commercially available plasmids such as pUC19 (2.7 kbp, Sigma Aldrich), pBR322 (4.4 kb, Sigma Aldrich), pET-40b(+) (6.2 kbp, Invitrogen), or pBACsurf-1 (9.5 kbp, Invitrogen).
In order to demonstrate the relevance of the topoisomer analysis, a plasmid topoisomer pattern is studied over the time course of the plasmid fermentation (Example 7). Cell mass samples containing bacterial cells are disrupted using NaOH/SDS. The suspension is centrifuged to obtain the cytoplasm content containing pDNA. Two-dimensional high-performance liquid chromatography (HPLC) approach is used, wherein in the first step a total pDNA is isolated from the mixture using size exclusion chromatography (SEC) and in the second dimension an allylcarbamoyl-10,1 1-dihydroquinine ligand-containing silica (shown in structure c) column is employed for ccc topoisomer separation. Fermentation samples, drawn in two-hour intervals, are analyzed by 2D HPLC. The results are shown as an overlay of chromatograms obtained after the second dimension (Figure 5a). The chromatograms shown are recorded from samples taken after 11 , 13, 15 and 17 hours from the beginning of the fermentation. The maximum of the topoisomer distribution, represented by the most populated ccc topoisomer (marked with an arrow in Figure 5a) is shifting during the fermentation. In this case the overall supercoiling shifts towards lower negative supercoiling. The entire progression of the distribution maximum is shown in Figure 5b. During the fermentation process the supercoiling of ccc pDNA changes significantly during the first hours of the fermentation but remains similar towards the end. These data support the importance of the topoisomer analysis which can be used as an indicator of the process stage and as a quality control parameter determined in a simple way by using liquid chromatography, and for the stability studies over the whole production process.
Brief Description of Figures
Figures 1 a to 1 c: Chromatograms recorded by UV absorption at 258 nm analyzing pDNA samples containing a mixture of ccc with oc and lin isoforms of the pMCP1 plasmid (4.9 kbp) during identical elution conditions.
Three columns are employed, each containing a te/f-butylcarbamoyl-quinine ligand attached to different silica matrixes (see structure f), namely 1.5 μηι non-porous particles (Figure 1 a), 10 μηι porous particles (Figure 1 b) and a monolith (Chromolith Si Performance, Merck) (Figure 3c). Elution conditions: Method 1 (see Example 4). "Y" axis reflects concentration of pDNA isoforms detected as UV absorption at 258 nm in milliabsorption units [mAU] in relation to "X" axis corresponding to retention time [min].
Figure 2: Chromatogram recorded by UV absorption at 258 nm from pDNA samples containing ccc, oc and lin isoforms of the pMCP1 plasmid (4.9 kbp) during pH- and 2-propanol mediated gradient elution conditions.
The three main peaks correspond to the three individual pDNA isoforms oc, lin, ccc (as denoted in the Figure 2). Elution conditions: Method 2. "Y" axis reflects concentration of pDNA isoforms detected as UV absorption at 258 nm in milliabsorption units [mAU] in relation to "X" axis corresponding to retention time [min]. Figure 3a and 3b: Chromatograms recorded by UV absorption at 258 nm analyzing pDNA samples with a high ccc content of the pMCP1 plasmid (4.9 kbp) during NaCI-mediated elution.
The ccc form in these chromatograms, eluting after the oc isoform, is split into a set of individual topoisomers. The resolution between the topoisomers is higher when using the te/f-butylcarbamoyl-quincorine ligand immobilized to
3-mercaptopropyl-modified silica shown in the structure d (Figure 3a) than when using the te/f-butylquincorinyl-urea ligand immobilized to 3-mercaptopropyl- modified silica shown in structure e (Figure 3b). "Y" axis reflects concentration of pDNA isoforms detected as UV absorption at 258 nm in milliabsorption units
[mAU] in relation to "X" axis corresponding to retention time [min].
Figure 3c: Chromatogram recorded by UV absorption at 258 nm after loading 284 Mg of a pDNA samples with a high ccc content of the pMCP1 plasmid (4.9 kbp). Elution is accomplished via NaCI gradient employing a
triethoxysilyl-activated propylcarbamoylquinine-ligand bound to 1.5 μιη non- porous silica.
The first peak represents the open circular (oc) isoform, while 21 topoisomers of the ccc isoform elute afterwards. "Y" axis reflects concentration of pDNA isoforms detected as UV absorption at 258 nm in absorption units [AU] in relation to "X" axis corresponding to retention time [min].
Figure 4a: Overlay of chromatograms recorded by UV absorption at 258 nm analyzing pDNA samples with a high ccc content of the pMCP1 plasmid (4.9 kbp) during NaCI-mediated elution employing a triethoxysilyl-activated propylcarbamoylquinine-ligand bound to 1.5 μιη non-porous silica.
The ccc form in these chromatograms, eluting after the oc isoform, is split into a set of individual topoisomers. A and B represent isolated topoisomer fractions. The dashed lines stand for fractions A and B reinjected after previous fractionation of the eluted topoisomers on the same column. "Y" axis reflects concentration of pDNA isoforms detected as UV absorption at 258 nm in milliabsorption units
[mAU] in relation to "X" axis corresponding to retention time [min]. Figure 4b: Capillary electrophorectic separation of the mixturecontaining fractions A and B, wherein the fractions are identical to A and B shown in Figure 4a.
The linear form is the fastest migrating form. Fraction B migrates faster than fraction A, thus indicating its smaller size and higher supercoiling. "Y" axis reflects concentration of pDNA isoforms detected as UV absorption at 258 nm in milliabsorption units [mAU] in relation to "X" axis corresponding to migration time [min]. Figure 5a: An overlay of chromatograms recorded by UV absorption at 258 nm from pDNA samples drawn during pDNA fermentation is obtained after 11 , 13, 15 and 17 hrs by employing the material disclosed as the structure b during NaCI-mediated gradient elution in the second
chromatographic dimension, i.e. upon purification step of crude samples. The arrow marks the highest abundant topoisomer within the topoisomer distribution and thus serves as an indicator of the overall supercoiling, obviously changing during fermentation. In all chromatograms with exception of Figure 4b, "Y" axis reflects concentration of pDNA isoforms detected as UV absorption at 258 nm in milliabsorption units [mAU] in relation to "X" axis corresponding to retention time [min].
Figure 5b: The maximum of the topoisomer distribution (calculated as maximum peak area) denoted as a relative linking number of the highest abundant topoisomer which is a measure of the overall supercoling (at the beginning of fermentation this value is zero) (y axis) is plotted against the entire duration of the fermentation (x axis).
Overall the topoisomer pattern changes during fermentation. Ύ" axis stands for the relative linking number ALk in relation to "X" axis reflecting the duration time [hours]. Examples
Example 1 : Scheme for synthesis of a ligand and coupling to a solid matrix. Scheme 1 : 980 mg (5 mmol) of (R)-(-)-1-Benzyl-3-hydroxypiperidine (Sigma Aldrich) are transferred into a three-necked round bottom flask and dissolved in 15 ml dichloromethane. The apparatus is flushed with nitrogen, and 502 μΙ (5.7 mmol, 1.15 eq.) allylisocyanate (Fluka) together with 3 μΙ (5 μηιοΙ)
dibutyltindilaurate (Aldrich) as a catalyst are added to the mixture. The yellowish solution is refluxed 3 hours and the reaction progress is monitored by tic
(dichloromethane: methanol = 20:1). After flash silica column chromatography using dichloromethane:methanol = 25: 1 as eluent, the product,
3-(allylcarbamoyloxy)-/\/-benzylpiperidine, is isolated in 58% yield.
3-mercaptopropyl-modified silica matrix (or support) is produced from bare 5 μηι spherical silica (30 g, Daiso, Japan) and 3-mercaptopropyl-methyldimethoxysilane (8.6 ml) by refluxing in dry toluene in the presence of 4-dimethylaminopyridine (57 mg, Fluka) for 7 hours. Endcapping is performed by refluxing the generated 3-mercaptopropyl-modified silica with 1 ,1 , 1 ,3,3,3-hexamethyldisilazane (Fluka) in toluene for 3 hours to form trimethylsilyl (TMS)-endcapped silanols. 330 mg (1.2 mmol) 3-(allylcarbamoyloxy)-/\/-benzylpiperidine and 2.05 g endcapped mercaptopropyl-modified 5 μηι silica are transferred into a three-necked round bottom flask equipped with a mechanical stirrer and suspended in 30 ml methanol. The apparatus is vigorously flushed while adding a solution of 5 mg azo-bis- (isobutyronitril) (AIBN, Merck) in 5 ml methanol. The mixture is refluxed for 20 hours under nitrogen atmosphere, and then it is filtrated through a sintered glass filter (porosity 3). After washing the silica material well with methanol, it is dried at 60°C for 48 hours. The synthesized material represents
3-(allylcarbamoyloxy)-/\/-benzylpiperidine immobilized onto 3-mercaptopropylsilica matrix (structure a).
Scheme 2: Thiol-modified organic polymer matrix is obtained as follows: reaction buffer is prepared by dissolving 178 mg disodiumhydrogenphosphate (Merck) in a mixture of 20 ml distilled water and 5 ml 2-propanol (Roth). The pH is adjusted to 8.0 with diluted orthophosphoric acid. 132.6 mg Suprema-Gel 30u (Polymer Standards Service-USA, Inc.) are suspended in 1.8 ml reaction buffer. Then, 192 μΙ of a solution of NaSH hydrate (Sigma Aldrich) in reaction buffer (100 mg/ml) is added, and the mixture is stirred for 2 hours at 63°C in a thermomixer
(Eppendorf). By means of a small glass funnel (porosity 3), the modified material is washed twice with reaction buffer, twice with water, once with 0.1 mol/l HCI, again with water, and twice with methanol.
Reduction of disulfides to terminal thiols: TCEP buffer is prepared by dissolving 672 mg sodiumdihydrogenphosphate in a mixture of 1 1.8 ml water and 2.8 ml methanol (measured pH is 4.6). Then, 19 mg (75 μηιοΙ) tris(2-carboxyethyl)- phosphine hydrochloride (TCEP) (Fluka) are dissolved in 1 ml of TCEP buffer. 34.5 mg of thiol-modified Suprema Gel is added to the solution and the mixture is stirred overnight at room temperature. The suspension is filtered through a small funnel and the material is washed with TCEP buffer, methanol and finally with hexane. Elemental analysis (54.52% carbon, 7.67% hydrogen, 1.40% sulphur) revealed a sulphur concentration of 0.44 mmol/g while no nitrogen is present. The concentration of reactive thiols is 0.14 mmol/g, as determined
spectrophotometrically (Nogueira et al., Analytica Chimica Acta, 2005, vol. 533 (2), pp. 179-183).
Ligand-modification: 14.4 mg of reduced thiol-modified Suprema-Gel 30u are transferred into a safe-lock plastic reaction tube (eppendorf). 130 μΙ of a 3.2 mg/ml solution of te/f-butylcarbamoylquinine (produced in-house) in methanol, 10 μΙ of a 2 mg/ml solution of AIBN (Merck) in methanol and 0.36 ml methanol are added and the mixture is purged with nitrogen. The reaction tube is stirred at 65°C for 18h. The suspension is filtered through a small funnel and the material is washed 3x with methanol and finally with petroleumether. Elemental analysis (50.27% carbon, 7.70% hydrogen, 0.11 % nitrogen, 0.97% sulphur) reveals a successful immobilization of the te/f-butylcarbamoylquinine ligand onto the thiol-modified organic polymer matrix (structure g).
Example 2: Impact of the linker's length on the recovery of plasmid isoforms.
Two solid supports for chromatography are synthesized bearing quinine- carbamate ligands, onto one of which the ligand is anchored via a short linker to the matrix (triethoxysilyl-activated propylcarbamoylquinine on bare silica, structure b), and onto the other matrix via a long linker (9-allylcarbamoyl-10, 11- dihydroquinine on 3-mercaptopropyl-modified silica, see structure c). The support with the long linker is synthesized according to Example 1 , Scheme 1 , starting from 10, 11-dihydroquinine (Buchler, Germany) and allylisocyanate (Sigma Aldrich) in 95% yield and attached to endcapped 3-mercaptopropyl-modified silica. The ligand density according to the elemental analysis (14.01 % C, 2.18% H, 1.38% N, and 1.90% S) is 318 μηιοΙ/g.
For the production of the matrix bearing the short linked ligand,
3-isocyanatopropyl-triethoxysilane (1 mol eq.) and quinine (1.05 mol eq.) are refluxed in methanol to yield the carbamate-containing product. Bare 5μηι spherical silica is added directly to the mixture (0.5 g of bare silica per mmol of quinine) while stirring mechanically and the suspension is refluxed further to obtain triethoxysilylpropylcarbamoylquinine-modified silica. After washing with methanol, the silanol groups are endcapped according to example 1 , scheme 1. The ligand density according to the elemental analysis (7.90%C, 1.21 % H, 0.911 % N) is 217 μι ιοΙ/g.
HPLC columns containing the produced supports are packed in-house with the modified 5 μηι silica stationary phases, at a pressure of 600 bar. HPLC analyses are carried out on an Agilent 1200 SL system (Waldbronn, Germany) equipped with a binary pump, a thermostatted autosampler (cooled to 4°C) and a DAD UV detector using a D2 lamp as UV source. Sample components are eluted by using Method 1 , i.e. an increasing NaCI gradient and an increasing 2-propanol gradient simultaneously ("mixed NaCI and 2-propanol gradient").
Eluents for HPLC and chromatographic conditions: Firstly, a 0.5 mol/L stock solution from NaH2P04 (Merck) is prepared. Eluent A consisted of 1 : 10 diluted stock solution (50 mmol/L NaH2P04) titrated to 7.0 with 5M NaOH. Eluent B consisted of 1 : 10 diluted stock solution (50 mmol/L NaH2P04) containing 0.6 mol/L NaCI (Fluka) and 10% (v/v) isopropanol (Roth) titrated to 7.0 with 5M NaOH. A gradient from 0 to 100%B in 15 minutes is run during analysis. The flow rate is set to 0.7 ml/min, detection wavelength to 258 nm (slit: 4nm, reference 360 nm with 100 nm bandwidth) and the temperature to 50°C (with preheating of the solvent in the 3 μΙ heat exchanger).
For recording chromatographic runs, 3 μΙ of a 2.84 mg/ml solution of a ccc pDNA sample containing 5% oc form (based on results of gel electrophoresis) is loaded onto the column and eluted with increasing amount of eluent B. After washing the column by injecting 4 times a 50 μΙ plug of 3 M NaCI while washing the column at 100% eluent B to assure the absence of a carry-over and reequilibrating the column at 0% B for 5 minutes, 20 μΙ of a 0.05 mg/ml solution of the oc isoform is loaded onto the column and eluted with increasing amount of eluent B. After further washing the column by injecting 4 times a 50 μΙ plug of 3 M NaCI and washing the column at 100% eluent B, 20 μΙ of a 0.05 mg/ml solution of the lin isoform is loaded onto the column and eluted with increasing amount of eluent B. When comparing the peak areas obtained for the oc and the linear isoform using the matrix with the long-linked ligand, the recovery (calculated as the ratio between the peak area per μg pDNA of the oc isoform and the peak are of the linear isoform per μg pDNA) is about 60%. However, when using the short-linked ligand the data are in conformity with each other within the analytical error (5%). When comparing the peak areas obtained for the ccc and the linear isoform samples, both supports tested show recoveries between 95 to 100%. Example 3: Impact of the matrix morphology on the separation of pDNA isoforms and topoisomers.
A te/f-butylcarbamoylquinine ligand synthesized from te/f-butylisocyanate and quinine in accordance to the procedure as described in Example 2 is attached via 3-mercaptopropylsilane activated support to 1.5 μηι non-porous silica particles (obtained from Micra Scientific Inc., USA), to 10 μηι porous silica particles
(obtained from Daiso Co, Ltd., Japan) and a silica monolith Chromolith™ (obtained from Merck, Germany) containing 2 μηι macropores. These supports have specific surface areas of 3 m2/g for the 1.5 μηι particles and 300 m2/g for the 10 μηι particles and the monolith, respectively. 1.5 μηι non-porous silica particles are packed into a 50 x 4.6 mm column by Bischoff Chromatography (Germany), while the 10 μηι particles are packed in-house at a pressure of 600 bar into a 150 x 4.0 mm column. The chromatographic equipment as well as the employed chromatographic conditions are disclosed in Example 2.
Samples containing all three isoforms are prepared by mixing 60 μΙ aqueous solution with 10 mM ethylenediaminetetraacetic acid disodium salt ("EDTA Na2", Fluka), 10 μΙ of a 2.84 g/μΙ ccc pDNA sample containing about 10% oc isoform, with 50 μΙ 0.05 g/μΙ linear isoform. Linear isoform is generated by digestion with EcoR V (Sigma Aldrich) according to the manufacturer's instructions and EDTA is added for inactivation of the endonuclease. In the chromatographic runs, 10 μΙ of these pDNA sample solutions containing all three isoforms of pDNA (oc, ccc and lin isoforms of the pMCPI plasmid) are loaded onto the columns and eluted under identical conditions. For the analytical purposes the 1.5 μηι support is the preferred choice. However, both the 10 μηι porous support (see Figure 1 b) and the monolithic support (see Figure 1 c) are suitable for preparative applications focusing merely on the separation of ccc form.
Example 4: Chromatographic method using a mixed pH and 2-propanol gradient elution (Method 2) in comparison to mixed NaCI / 2-propanol gradient elution (Method 1 ).
100 μΙ of a pDNA sample, containing 0.15 μg oc isoform, 0.3 μg linear isoform and 14.2 μg ccc isoform, are loaded onto a material comprising of a
triethoxysilylpropylcarbamoylquinine ligand (see structure b) attached to 1.5 μηι non-porous silica. Sample components are eluted using Method 2, i.e. an increasing pH gradient and an increasing 2-propanol gradient simultaneously ("mixed pH and 2-propanol gradient") on an Agilent 1200 SL system recording the UV absorption at 258 nm.
Eluents for HPLC and chromatographic conditions: First, a 0.5 mol/L stock solution from NaH2P04 (Merck, Darmstadt, Germany) is prepared. Eluent A consisted of 1 :10 diluted stock solution (50 mmol/L NaH2P04) titrated to 7.2 with 5M NaOH. Eluent B consisted of 1 : 10 diluted stock solution (50 mmol/L NaH2P04) and 20% (v/v) 2-propanol titrated to 7.9 with 5M NaOH. A linear gradient from 0 to 100%B (corresponding to a gradient from pH 7.2 to pH 7.9) in 15 minutes is run during analysis. Between the analytic runs, the column is washed by a plug of sodium chloride (injection of 50μΙ 3M NaCI (aq.)) while the mobile phase composition is kept at 80% B for 1 minute, followed by reequilibration to 0% B for 5 minutes. The flow rate is set to 0.7 ml/min, detection wavelength to 258 nm (slit 4 nm, reference 360 nm with 100 nm bandwidth) and the temperature to 60°C (with preheating of the solvent in the 3 μΙ heat exchanger). When comparing these chromatograms to those obtained in Method 1 described in Example 2 (see Figure 1 a), the latter one is preferred for separation of pDNA topisomers. Method 2 is preferred for the analytical determination of the plasmid homogeneity, i.e. the content of the ccc form relatively to the other forms (oc and linear), as well as for preparative application for isolation of ccc pDNA (without topoisomer separation). Example 5: Demonstration of ligand variation and high loadability.
Three solid supports for chromatography are synthesized. The tert- butylcarbamoyl-quincorine ligand (structure d) is synthesized according to Example 1 , Scheme 1 , starting from quincorine (Buchler, Germany) and tert- butylisocyanate and performing flash silica column chromatography in ethyl acetate (redistilled in-house) / triethylamine (Fluka) (10:1) in 96% yield and attached to endcapped mercaptopropyl-modified 5 μηι silica particles. The ligand density according to the elemental analysis (10.51 % C, 1.98% H, 0.979% N, 1.85% S) is 307 μηιοΙ/g.
The te/f-butylquincorinylurea ligand (structure e) is synthesized according to Example 1 , Scheme 1 , starting from quincorine-amine (Buchler, Germany) and te/f-butylisocyanate and performing flash silica column chromatography in ethyl acetate (redistilled in-house) / methanol / triethylamine (Fluka) (10: 1 :1) in 96% yield and attached to endcapped 3-mercaptopropyl-modified 5 μηι silica particles. The ligand density according to the elemental analysis (8.965% C, 1.87% H, 0.979% N, 1.94% S) is 210 μΓΤΐοΙ/g.
The triethoxysilylpropylcarbamoylquinine-modified silica matrix is produced according to Example 2, using 1.5 μηι non-porous silica particles (Micra Scientific Inc., USA). The ligand density according to the elemental analysis is 9 μΓΤΐοΙ/g due to 100 x smaller specific surface area. The triethoxysilylpropylcarbamoylquinine- modified silica material is packed into 4.6 x 50 mm columns, while the other two materials are packed into 150 x 4.0 mm columns.
Eluents for HPLC and chromatographic conditions: Firstly, a 0.5 mol/L stock solution from NaH2P04 (Merck) is prepared. Eluent A consisted of 1 : 10 diluted stock solution (50 mmol/L NaH2P04) titrated to 7.0 with 5M NaOH. Eluent B consisted of 1 : 10 diluted stock solution (50 mmol/L NaH2P04) containing 0.6 mol/L NaCI (Fluka) and 30% (v/v) isopropanol (Roth) titrated to 7.0 with 5M NaOH. A gradient from 60 to 100%B in 24 minutes (te/f-butylcarbamoyl-quincorine and te/f-butylquincorinylurea ligand) or 0 to 25%B in 15 minutes
(triethoxysilylpropylcarbamoylquinine ligand) is run during analysis. The flow rate is set to 0.7 ml/min, detection wavelength to 258 nm (slit: 4nm, reference 360 nm with 100 nm bandwidth) and the temperature to 60°C (with preheating of the solvent in the 3 μΙ heat exchanger). For recording chromatographic runs (Figure 5c, 5d and 6a), 3 μΙ of a 2.84 mg/ml solution of a ccc pDNA sample solution containing 5% oc form is loaded onto the column and eluted with increasing amount of eluent B. For demonstrating high loadability, 100 μΙ of the sample solution containing 284 μg total pDNA are loaded onto the 4.6 x 50 mm column and eluted with increasing amount of eluent B.
Roughly estimated, the column contains about 0.5 g of the chromatographic material which is found to be sufficient for separating 284 μg total pDNA. All ligands according to the invention are able to separate pDNA isoforms and topoisomers confirmed by the same elution pattern, thus demonstrating the robustness of the chemoaffinity principle.
Example 6: Demonstration of topoisomer identity and its elution order.
A matrix containing an allylcarbamoyl-10, 11-dihydroquinine ligand (see Figure 2b) is synthesized according to example 1 , scheme 1 and packed in-house into 150 x 4.0 mm columns. The chromatographic system and chromatographic conditions are as described in example 5, except for the gradient which was run from 10 to 60%B in 30 min.
For recording chromatographic runs, 100 μΙ of a 2.84 mg/ml solution of a ccc pDNA sample containing about 4% oc form is loaded onto the column and eluted with increasing amount of eluent B. During the run, two fractions are collected after the UV detector each containing a single topoisomer. The fractions are dialyzed against purified water using a VSWP cellulose ester membrane (25 mm diameter, 25 nm pores) supplied by Millipore (MA, USA). The discs are put on the water surface with the shiny side up and a volume of 300 μΙ is loaded onto the disc surface carefully. After floating for 15 to 30 minutes at 4°C, the samples are recovered with a pipette and 20 μΙ of this solution from each fraction is re-injected into the chromatographic system.
Capillary gel electrophoresis is performed in a 3DCE instrument from Agilent Technologies. A DB-17 coated capillary with 100 μηι i.d. is purchased from J&W Scientific (Folsom, CA), cut to a length of 32 cm and a detection window is made by removing the polyimide coating with a razor blade (effective length 24.5 cm). For topoisomer analysis, the capillary is filled with Tris-borate-EDTA (TBE, 89 mM boric acid, 89 mM Tris, 2 mM EDTA, titrated to pH 9.0 with NaOH) buffer containing 0.1 % hydroxypropylmethylcellulose (HPMC, 86 kDa) purchased from Acros organics (Geel, Belgium). For complete homogenization of the buffer, the solution is stirred for 24 h after addition of the biopolymer and afterwards let to stand for another 24 h without disturbing at room temperature. For gaining higher resolution of highly supercoiled ccc plasmids, an intercalator is added to the electrophoresis buffer [de Carmejane et al., Proceedings of SPIE-The International Society for Optical Engineering, 1999, vol. 3602, p.346-354], in this case 12 μΙ of a 5 mg/ml aqueous chloroquine diphosphate (Fluka) solution to 4 ml of
electrophoresis buffer to give a final concentration of 15 μg/ml chloroquine, respectively. Samples are introduced by electrokinetic injection at -5 kV for 4 seconds. Electrophoresis is then performed in negative mode at 3.3 kV for
25 minutes at 25°C, with UV detection at 258 nm. Before injection, the capillary is flushed with water for 3 minutes and then preconditioned with running buffer for 5 minutes. Overall, during the elution of individual topoisomers, it is found that those which are being less negatively supercoiled elute firstly.
Example 7: In-process control of topoisomer distribution during
biotechnological production of plasmid DNA.
During a batch fermentation of a pDNA encoded as AS24 (4.4 kb, Boehringer Ingelheim) in E.coli, samples are drawn in 2 hour intervals and frozen immediately. Before analysis, the samples are thawed and the pDNA is isolated and
concentrated using a MiniPrep Kit (Qiagen) according to the manufacturer's instructions. The crude plasmid samples are directly injected into a two- dimensional HPLC system and analyzed.
Chromatographic conditions: 2D HPLC system (biocompatible Ultimate 3000 by Dionex), containing two additional 10-1 column switching valves
1 st dimension: SRT SEC 1000 (size exclusion column) by Sepax Technologies Inc. (USA), Eluent: 0.1 mol/l Tris (Fluka) with 0.1 mol/l NaCI and 1 mmol/l EDTA, pH 7.5 (isocratic elution), flow rate: 2.0 ml/min
2nd dimension: 100 x 4.0 mm column with 5 μηι silica containing ligand as disclosed in Figure 2b, Eluent A: 50 mM phosphate buffer pH 7.2, Eluent B:
Eluent A with 0.6 mol/l NaCI and 10% (v/v) isopropanol pH 7.2, column
temperature 60°C, flow rate 1.0 ml/min, det. UV 258 nm; linear gradient 0 - 100%B in 15 min, inj. vol. 20 μΙ. During the fermentation process the supercoiling of ccc pDNA changes significantly, which is reliable determined by using the method of separation of pDNA topoisomers according to the invention.
Example 8: Cinchorine-type ligand on CIM monolith.
A CIM® Epoxy Disk Monolithic Column (BIA Separations) is rinsed with a freshly prepared 2 M solution of sodium hydrogen sulfide (Sigma-Aldrich) in a mixture of methanol and 0.1 M aqueous sodium dihydrogenphosphate (Merck), (20:80, v/v) (pH 8.15) in flow through-mode with an HPLC pump for 2h. Afterwards, the column is washed with methanol/water (20:80, v/v) and then with methanol.
A 0.25 M solution of te/f-butylcarbamoylquincorine (structure d) is prepared by dissolving it in methanol, and α,α'-azoisobutyronitrile (AIBN) (6 mg/ml, 0.037 M) is added as radical initiator. The mixture is sonicated for 5 min, filtered through a Nylon membrane, and purged with nitrogen for 10 min. Then, this tert- butylcarbamoylquincorine-solution is pumped into the thiol-functionalised CIM disc column. The column is sealed at both ends and transferred to a water bath, where the radical addition of the chromatographic ligand occurred at 60°C. After 24 hours the column is removed from the water bath, rinsed with methanol and then equilibrated with mobile phase using an HPLC pump. The separation of the plasmid isoforms is carried out using elution Method 1 (NaCI-gradient) with organic matrix, particularly suitable for preparative purposes.
Example 9: Modification of epoxy-group containing non-porous organic polymer particles.
Epoxy-modified nonporous polymethacrylate beads (epoxy-NPR, 2.5 μηι from Tosoh) are suspended in methanol in a three-necked round bottom flask. A 2 M solution of sodium hydrogen sulfide in a mixture of methanol and 0.1 M aqueous sodium dihydrogenphosphate, (20:80, v/v) (pH 8.15) is added (10-fold molar excess related to epoxy groups) and stirred under nitrogen flow for 2h. Afterwards, the particles are filtered and washed with methanol/water (20:80, v/v) and then with methanol. A 0.25 M solution of te/f-butylcarbamoylquincorine (structure d) is prepared by dissolving it in methanol, and α,α'-azoisobutyronitrile (AIBN)
(6 mg/ml, 0.037 M) is added as radical initiator. The mixture is sonicated for 5 min, filtered through a Nylon membrane, and purged with nitrogen for 10 min. Then, this te/f-butylcarbamoylquincorine-solution is added to a suspension of the above synthesized thiol-modified NPR particles in the three-necked round bottom flask. The radical addition reaction for bonding of the selector to the thiol-functionalised beads is carried out by stirring at 60°C for 24 hours under a stream of nitrogen. Then, the particles are filtered and washed several times with methanol.
The particles are slurry packed into stainless steel column of the dimension 33 x 4.6 mm ID. The testing of the column for the separation of the plasmid isoforms is carried out using elution Method 1 (simultaneous NaCI- and 2-propanol gradients) with organic matrix, particularly suitable for analytical purposes.

Claims

Claims
1. Use of a material comprising a ligand according to formula 1
Figure imgf000044_0001
wherein the ligand contains a cationic group (C) and a hydrogen donor group (N-H) connected by a spacer with a length between 3 to 5 atoms,
m, o and r are independently from one another either 0 or 1 , and
k, I, n and p are independently from one another either 0, 1 or 2, and
Y is any moiety selected from the group -CH2-, -0-, -N H- or -S-,
Z is any moiety selected from the group -C-, -S-, or -P- , and
RL R2 and R3 are anyone of the substituents from the group consisting of hydrogen, CMS branched or unbranched alkyl, C2-is branched or unbranched alkenyl, C2-is branched or unbranched alkynyl, C3.n-carbocycle ,
C3-8-heterocycle , C5.i8-aryl and C5.i3-heteroaryl,
wherein R^ R2 and R3 optionally comprise independently from one another one or more moieties selected from the group -S-, -0-, -NH-, and
each of R^ R2, R3 can be optionally and independently substituted with one or more substituents selected from the group consisting of hydrogen,
Ci-6 branched or unbranched alkyl, C2.6 branched or unbranched alkenyl, C2-6 branched or unbranched alkynyl, C3.8-carbocycle, C3.8-heterocycle and C5-io-aryl, C5-io-heteroaryl, and
whereby the cationic group C is a C3_n heterocycle comprising at least one nitrogen atom and optionally another heteroatom selected from the group consisting of sulphur, oxygen, nitrogen and phosphorus, or C5.i8 heteroaryl comprising at least one nitrogen atom and optionally another heteroatom selected from the group consisting of sulphur, oxygen, nitrogen and phosphorus, or
branched or unbranched CM0 alkyl, branched or unbranched C2_i0 alkenyl, branched or unbranched C2_i0 alkynyl comprising at least one nitrogen atom and optionally another heteroatom selected from the group consisting of sulphur, oxygen, nitrogen and phosphorus,
wherein C and R3 or C and R2 are optionally linked to each other by forming a ring, and
wherein the ligand is optionally immobilized onto or embedded into a matrix via Ri or R3 group,
for the separation of plasmid DNA isoforms or topoisomers.
The use according to claim 1 wherein the spacer length is equal to 4 atoms.
The use according to claim 1 or 2 wherein is anyone of the substituents selected from the group consisting of hydrogen, Ci_8 branched or unbranched alkyl, C2.8 branched or unbranched alkenyl and C2.8 branched or unbranched alkynyl, optionally comprising one or more sulphur atoms.
The use according to claim 1 or 2 wherein is anyone of the substituents selected from the group consisting of C3.8-carbocycle, C5.8-heterocycle, C5.io-aryl and C5.9-heteroaryl.
The use according to one of claims 1 to 4 wherein R3 is anyone of the substituents selected from the group consisting of hydrogen, Ci_8 branched or unbranched alkyl, C2.8 branched or unbranched alkenyl and C2.8 branched or unbranched alkynyl, optionally comprising one or more sulphur atroms.
The use according to one of claims 1 to 4 wherein R3 is a C5.i0 aryl or C5.i0 aryl heteroaryl.
7. The use according to one of claims 1 to 6 wherein the hydrogen donor group (N-H) is located adjacent to at least one hydrogen acceptor selected from a group consisting of carbonyl (C=0), sulfonyl (-S02-) and phosphonyl group (-P(=0)-).
8. The use according to claim 7 wherein the hydrogen acceptor is carbonyl group
(C=0).
9. The use according to one of claims 1 to 8 wherein o = 0 and m = 1.
10. The use according to one of claims 1 to 8 wherein o = 1 and m = 0.
1 1. The use according to one of claims 1 to 8 wherein o = 0 and m = 1 , and
wherein k = 1 and I = 1 , Z is -C- and n = 1.
12. The use according to one of claims 1 to 8 wherein o = 1 and m = 0, and
wherein k = 1 and I = 1 , Z is -C- and p = 1.
13. The use according to one of claims 1 to 12 wherein the matrix is solid or liquid, and selected from organic or inorganic polymers, wherein the inorganic polymer is silica based or zirconium oxide, and wherein the organic polymer is polymethacrylate or agarose based.
14. The use according to claim 13 wherein the matrix is a particle, a monolith
resin, a membrane, or a magnetic bead.
15. The use according to one of claims 1 to 14 wherein the plasmid DNA isoforms are covalently closed circular (ccc), open circular (oc) or linear (lin) forms. 16. The use according to claim 15 wherein the plasmid DNA isoforms comprise mixtures of monomers, dimers, trimers, tetramers, oligomers, or multimers, wherein the oligomeric and multimeric plasmid DNA is in form of catenane or concatemer.
17. The use according to one of claims 1 to 16 wherein the material is selected from a group consisting of:
structure (b)
Figure imgf000047_0001
structure (f)
Figure imgf000048_0001
and structure (g)
Figure imgf000048_0002
18. A material selected from a group consisting of:
Figure imgf000049_0001
19. Use of the material according to claim 18 for the separation of plasmid DNA isoforms or topoisomers.
20. A method for chromatographic separation of plasmid DNA isoforms or topoisomers by using the material according to one of claims 1 to 19.
21. The method according to claim 20 comprising steps of: a. dilution/dissolution of a sample containing pDNA isoforms or topoisomers
b. loading of the sample onto the material
c. washing of the bound sample
d. elution of the sample from material
e. detecting and/or collecting eluted fractions
PCT/EP2012/053241 2011-02-28 2012-02-27 Liquid phase separation of plasmid dna isoforms and topoisomers Ceased WO2012116945A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2013555837A JP2014512805A (en) 2011-02-28 2012-02-27 Liquid phase separation of plasmid DNA isoforms and topological isomers
KR1020137023749A KR20140033006A (en) 2011-02-28 2012-02-27 Liquid phase separation of plasmid dna isoforms and topoisomers
SG2013065024A SG192983A1 (en) 2011-02-28 2012-02-27 Liquid phase separation of plasmid dna isoforms and topoisomers
AU2012222502A AU2012222502A1 (en) 2011-02-28 2012-02-27 Liquid phase separation of plasmid DNA isoforms and topoisomers
EP12705871.7A EP2680932A2 (en) 2011-02-28 2012-02-27 Liquid phase separation of plasmid dna isoforms and topoisomers
CA2825248A CA2825248A1 (en) 2011-02-28 2012-02-27 Liquid phase separation of plasmid dna isoforms and topoisomers
CN201280020769.9A CN103501871A (en) 2011-02-28 2012-02-27 Liquid phase separation of plasmid dna isoforms and topoisomers

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11156235.1 2011-02-28
EP11156235 2011-02-28

Publications (2)

Publication Number Publication Date
WO2012116945A2 true WO2012116945A2 (en) 2012-09-07
WO2012116945A3 WO2012116945A3 (en) 2012-12-13

Family

ID=44168483

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/053241 Ceased WO2012116945A2 (en) 2011-02-28 2012-02-27 Liquid phase separation of plasmid dna isoforms and topoisomers

Country Status (9)

Country Link
US (1) US20120220729A1 (en)
EP (1) EP2680932A2 (en)
JP (1) JP2014512805A (en)
KR (1) KR20140033006A (en)
CN (1) CN103501871A (en)
AU (1) AU2012222502A1 (en)
CA (1) CA2825248A1 (en)
SG (1) SG192983A1 (en)
WO (1) WO2012116945A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013021027A3 (en) * 2011-08-09 2013-04-25 Ralph Markus Wirtz Matrix and method for purifying and/or isolating nucleic acids

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016197491A1 (en) * 2015-06-12 2016-12-15 Institute Of Genetics And Developmental Biology, Chinese Academy Of Sciences A three-dimensional tissue scaffold with stem cell attracting element and use thereof
CN107688055A (en) * 2016-08-03 2018-02-13 湖北生物医药产业技术研究院有限公司 Detection method for nucleic acid drug linear DNA content
CN113440598B (en) * 2020-03-24 2023-08-01 深圳翰宇药业股份有限公司 Topological impurity stabilizing method
CN111721871A (en) * 2020-06-24 2020-09-29 南京济群生物科技有限公司 High-resolution detection method for plasmid supercoiled DNA content

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992020677A1 (en) 1991-05-13 1992-11-26 Massachusetts Institute Of Technology Heterocyclic chiral ligands and method for catalytic asymmetric dihydroxylation of olefins
WO1997046557A1 (en) 1996-06-05 1997-12-11 Wolfgang Lindner Cinchonan based chiral selectors for separation of stereoisomers
US6197994B1 (en) 1998-03-26 2001-03-06 Korea Institute Of Science And Technology Silica gel supported bis-cinchona alkaloid derivatives and a preparation method and use thereof
US6616825B1 (en) 2000-08-23 2003-09-09 The Regents Of The University Of California Electrochromatographic device for use in enantioselective separation, and enantioselective separation medium for use therein
EP1187840B1 (en) 1999-05-28 2009-06-10 Lonza Biologics Inc. Methods of dna purification

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003250322B2 (en) * 2002-08-14 2010-01-21 Neurosearch A/S Novel quinuclidine derivatives and their use
JP4291628B2 (en) * 2003-06-12 2009-07-08 株式会社資生堂 Liquid chromatograph apparatus and method for analyzing optical isomers contained in sample
EP1693108A1 (en) * 2004-12-04 2006-08-23 MERCK PATENT GmbH Mixed-modal anion-exchange type separation material

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992020677A1 (en) 1991-05-13 1992-11-26 Massachusetts Institute Of Technology Heterocyclic chiral ligands and method for catalytic asymmetric dihydroxylation of olefins
WO1997046557A1 (en) 1996-06-05 1997-12-11 Wolfgang Lindner Cinchonan based chiral selectors for separation of stereoisomers
US6197994B1 (en) 1998-03-26 2001-03-06 Korea Institute Of Science And Technology Silica gel supported bis-cinchona alkaloid derivatives and a preparation method and use thereof
EP1187840B1 (en) 1999-05-28 2009-06-10 Lonza Biologics Inc. Methods of dna purification
US6616825B1 (en) 2000-08-23 2003-09-09 The Regents Of The University Of California Electrochromatographic device for use in enantioselective separation, and enantioselective separation medium for use therein

Non-Patent Citations (38)

* Cited by examiner, † Cited by third party
Title
DE CARMEJANE ET AL., PROCEEDINGS OF SPIE-THE INTERNATIONAL SOCIETY FOR OPTICAL ENGINEERING, vol. 3602, 1999, pages 346 - 354
DEPEW, R. E.; WANG, J. C., PROC. NATL. ACAD. SCI. U. S. A., vol. 72, 1975, pages 4275 - 4279
DIOGO, M. M. ET AL., JOURNAL OF CHROMATOGRAPHY, A, vol. 1069, 2005, pages 3 - 22
DIOGO, M.M. ET AL., JOURNAL OF CHROMATOGRAPHY A, vol. 1069, 2005, pages 3 - 22
FDA, U.: "Administration", 2007, article "Considerations for Plasmid DNA Vaccines for Infectious Disease Indications"
FERREIRA, G.N.M. ET AL., PHARM. PHARMACOL. COMMUN., vol. 5, 1999, pages 57 - 59
FINKELSTEIN D. B. ET AL., J. BIOCHEMISTRY, vol. 11, 25, 1972, pages 4853 - 8
HAHN, R., SEPARATION SCIENCE AND TECHNOLOGY, vol. 37, 2002, pages 1545 - 1565
HAN Y.; GARETH M.F., J. CHROMATOGR. B, vol. 874, 2008, pages 21 - 26
HUBER, C. G., JOURNAL OF CHROMATOGRAPHY, A, vol. 806, 1998, pages 3 - 30
LAEMMERHOFER M. ET AL., JOURNAL OF CHROMATOGRAPHY, A, vol. 741, 1996, pages 33 - 48
LAHIJANI, R. ET AL., HUMAN GENE THERAPY, vol. 7, 1996, pages 1971 - 1980
LEE Y.-K. ET AL., POLYMER, vol. 43, 2002, pages 7539 - 7547
MOLLOY ET AL., NUCLEIC ACID RESEARCH, vol. 32, 2004, pages E129,121 - E129,110
MONAGHAN-CANNON M.; DUNICAN L. K., THE BIOCHEMICAL JOURNAL, vol. 115, no. 3, 1969, pages 7P
NOGUEIRA ET AL., ANALYTICA CHIMICA ACTA, vol. 533, no. 2, 2005, pages 179 - 183
ONISHI, Y. ET AL., ANALYTICAL BIOCHEMISTRY, vol. 210, 1993, pages 63 - 68
ROZING, G. P., JOURNAL OF CHROMATOGRAPHY A, vol. 476, 1989, pages 3 - 19
SANDBERG, L.M. ET AL., JOURNAL OF BIOTECHNOLOGY, vol. 109, 2004, pages 193 - 199
SCHLEEF, M.: "Plasmids for Therapy and Vaccination", 2001, WILEY-VCH
SCHMIDT, T. ET AL., ANALYTICAL BIOCHEMISTRY, vol. 274, 1999, pages 235 - 240
SMITH, C. R. ET AL., JOURNAL OF CHROMATOGRAPHY, B: ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, vol. 854, 2007, pages 121 - 127
SOUSA A ET AL., J. SEP. SCI., vol. 33, 2010, pages 2610 - 2618
SOUSA A. ET AL., J. SEP. SCI., vol. 33, 2010, pages 2610 - 2618
SOUSA F. ET AL., TRENDS IN BIOTECHNOLOGY, vol. 26, no. 9, 2008, pages 518 - 525
SOUSA F.; QUEIROZ J.A., J OF CHROMATOGRAPHY A
SOUSA, F. ET AL., ANALYTICAL BIOCHEMISTRY, vol. 343, 2005, pages 183 - 185
STADLER J. ET AL., J GENE MED, vol. 6, 2004, pages 554 - 566
TIAINEN P. ET AL., JOURNAL OF CHROMATOGRAPHY A, vol. 1138, 2007, pages 84 - 94
TIAINEN, P. ET AL., JOURNAL OF CHROMATOGRAPHY, A, vol. 1149, 2007, pages 158 - 168
URTHALER J. ET AL., CHEMICAL ENGINEERING AND TECHNOLOGY, vol. 28, 2005, pages 1408 - 1420
URTHALER, J. ET AL., JOURNAL OF BIOTECHNOLOGY, vol. 128, 2007, pages 132 - 149
URTHALER, J. ET AL., JOURNAL OF CHROMATOGRAPHY, A, vol. 1065, 2005, pages 93 - 106
URTHALER, J., CHEMICAL ENGINEERING & TECHNOLOGY, vol. 28, 2005, pages 1408 - 1420
WIEDER, W. ET AL., JOURNAL OF SEPARATION SCIENCE, vol. 29, 2006, pages 2478 - 2484
WOELFLE, M.A., PNAS, vol. 104, no. 47, 2007, pages 18819 - 18824
WU, L.; PANG, G.-C., CHROMATOGRAPHIA, vol. 66, 2007, pages 151 - 157
Y. HAN ET AL., J. CHROMATOGR. B, vol. 874, 2008, pages 21 - 26

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013021027A3 (en) * 2011-08-09 2013-04-25 Ralph Markus Wirtz Matrix and method for purifying and/or isolating nucleic acids
US9683229B2 (en) 2011-08-09 2017-06-20 Ralph Markus Wirtz Matrix and method for purifying and/or isolating nucleic acids

Also Published As

Publication number Publication date
CA2825248A1 (en) 2012-09-07
AU2012222502A1 (en) 2013-08-01
SG192983A1 (en) 2013-09-30
WO2012116945A3 (en) 2012-12-13
JP2014512805A (en) 2014-05-29
KR20140033006A (en) 2014-03-17
CN103501871A (en) 2014-01-08
US20120220729A1 (en) 2012-08-30
EP2680932A2 (en) 2014-01-08

Similar Documents

Publication Publication Date Title
US11845772B2 (en) Ribonucleic acid purification
JP4440474B2 (en) Chromatographic separation and selective adsorbent
US20040002081A1 (en) Method and device for isolating and purifying a polynucleotide of interest on a manufacturing scale
US20120220729A1 (en) Liquid phase separation of plasmid dna isoforms and topoisomers
KR20210134639A (en) Purification of biological molecules such as plasmid DNA using anion exchange chromatography
RO122855B1 (en) Dna purifying method and purified dna
US20070161000A1 (en) Plasmid purification
US20040127648A1 (en) Sorbent and method for the separation of plasmid DNA
WO2016130928A1 (en) Aminoglycoside hydrogel microbeads and macroporous gels with chemical crosslink, method of preparation and use thereof
EP1321176A1 (en) Method and device for isolating and purifying a polynucleotide of interest on a manufacturing scale
CN104470606A (en) Chromatographic purification of polynucleotides with negatively charged particles
WO2017115652A1 (en) Separation and analysis method
WO2001037987A1 (en) A method for selective removal of a substance from samples containing compounds having nucleic acid structure
Yu et al. RECENT DEVELOPMENT AND APPLICATION OF MONOLITHIC COLUMNS.
HK1189849A (en) Liquid phase separation of plasmid dna isoforms and topoisomers
JP2025515479A (en) Method for pre-screening adeno-associated virus capsids and method for isolating same
US9610576B2 (en) Hydrolytically stable ion-exchange stationary phases and uses thereof
US20090047734A1 (en) Method of separation of deoxyribonucleic acids
WO2017115655A1 (en) Separation and analysis method
JP2006507825A (en) Isolation of antisense oligonucleotides
WO2003051484A1 (en) Separation method
CN118871580A (en) Method for reducing endotoxin levels in nucleic acid purification
CN121941767A (en) Method for purifying plasmid DNA
KR20260046476A (en) Method for purifying plasmid DNA
KR20250092189A (en) Chromatographic apparatus, system, and use thereof for analytical separation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12705871

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2825248

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2012222502

Country of ref document: AU

Date of ref document: 20120227

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2013555837

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20137023749

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2012705871

Country of ref document: EP